<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:47:36Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3581774" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3581774</identifier><datestamp>2013-04-01</datestamp><setSpec>elsevierwt</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Neurobiol Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Neurobiol. Dis</journal-id>
      <journal-title-group>
        <journal-title>Neurobiology of Disease</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0969-9961</issn>
      <issn pub-type="epub">1095-953X</issn>
      <publisher>
        <publisher-name>Academic Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3581774</article-id>
      <article-id pub-id-type="pmcid">PMC3581774</article-id>
      <article-id pub-id-type="pmc-uid">3581774</article-id>
      <article-id pub-id-type="pmid">23238346</article-id>
      <article-id pub-id-type="publisher-id">S0969-9961(12)00384-1</article-id>
      <article-id pub-id-type="doi">10.1016/j.nbd.2012.12.001</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Novel missense mutations in the glycine receptor Î² subunit gene (<italic>GLRB</italic>) in startle disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>James</surname>
            <given-names>Victoria M.</given-names>
          </name>
          <xref rid="af0005" ref-type="aff">a</xref>
          <xref rid="af0010" ref-type="aff">b</xref>
          <xref rid="fn0005" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bode</surname>
            <given-names>Anna</given-names>
          </name>
          <xref rid="af0015" ref-type="aff">c</xref>
          <xref rid="fn0005" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chung</surname>
            <given-names>Seo-Kyung</given-names>
          </name>
          <xref rid="af0020" ref-type="aff">d</xref>
          <xref rid="af0025" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gill</surname>
            <given-names>Jennifer L.</given-names>
          </name>
          <xref rid="af0005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nielsen</surname>
            <given-names>Maartje</given-names>
          </name>
          <xref rid="af0030" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cowan</surname>
            <given-names>Frances M.</given-names>
          </name>
          <xref rid="af0035" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vujic</surname>
            <given-names>Mihailo</given-names>
          </name>
          <xref rid="af0035" ref-type="aff">g</xref>
          <xref rid="af0040" ref-type="aff">h</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thomas</surname>
            <given-names>Rhys H.</given-names>
          </name>
          <xref rid="af0020" ref-type="aff">d</xref>
          <xref rid="af0025" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rees</surname>
            <given-names>Mark I.</given-names>
          </name>
          <xref rid="af0020" ref-type="aff">d</xref>
          <xref rid="af0025" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Harvey</surname>
            <given-names>Kirsten</given-names>
          </name>
          <xref rid="af0005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Keramidas</surname>
            <given-names>Angelo</given-names>
          </name>
          <xref rid="af0015" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Topf</surname>
            <given-names>Maya</given-names>
          </name>
          <xref rid="af0010" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ginjaar</surname>
            <given-names>Ieke</given-names>
          </name>
          <xref rid="af0030" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lynch</surname>
            <given-names>Joseph W.</given-names>
          </name>
          <xref rid="af0015" ref-type="aff">c</xref>
          <xref rid="af0045" ref-type="aff">i</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Harvey</surname>
            <given-names>Robert J.</given-names>
          </name>
          <email>r.j.harvey@ucl.ac.uk</email>
          <xref rid="af0005" ref-type="aff">a</xref>
          <xref rid="cr0005" ref-type="corresp">â</xref>
        </contrib>
      </contrib-group>
      <aff id="af0005"><label>a</label>Department of Pharmacology, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom</aff>
      <aff id="af0010"><label>b</label>Institute for Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, London WC1E 7HX, United Kingdom</aff>
      <aff id="af0015"><label>c</label>Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072 Australia</aff>
      <aff id="af0020"><label>d</label>Institute of Life Science, College of Medicine, Swansea University, Swansea SA2 8PP, United Kingdom</aff>
      <aff id="af0025"><label>e</label>Wales Epilepsy Research Network, College of Medicine, Swansea University, Swansea SA2 8PP, United Kingdom</aff>
      <aff id="af0030"><label>f</label>Center for Human 2333 ZC Leiden, and Clinical Genetics, Leiden University Medical Center, Einthovenweg 20, The Netherlands</aff>
      <aff id="af0035"><label>g</label>Department of Paediatrics, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0HS, United Kingdom</aff>
      <aff id="af0040"><label>h</label>Department of Clinical Genetics, Sahlgrenska University Hospital, SE-41345, Gothenburg, Sweden</aff>
      <aff id="af0045"><label>i</label>School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia</aff>
      <author-notes>
        <corresp id="cr0005"><label>â</label>Corresponding author at: Department of Pharmacology, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom. <email>r.j.harvey@ucl.ac.uk</email></corresp>
        <fn id="fn0005">
          <label>1</label>
          <p>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>4</month>
        <year>2013</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2013</year>
      </pub-date>
      <volume>52</volume>
      <fpage>137</fpage>
      <lpage>149</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>9</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>26</day>
          <month>11</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>12</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2013 Elsevier Inc.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Elsevier Inc.</copyright-holder>
        <license xlink:href="https://creativecommons.org/licenses/by/3.0/">
          <license-p>Open Access under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/3.0/">CC BY 3.0</ext-link> license</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Startle disease is a rare, potentially fatal neuromotor disorder characterized by exaggerated startle reflexes and hypertonia in response to sudden unexpected auditory, visual or tactile stimuli. Mutations in the GlyR Î±<sub>1</sub> subunit gene (<italic>GLRA1</italic>) are the major cause of this disorder, since remarkably few individuals with mutations in the GlyR Î² subunit gene (<italic>GLRB</italic>) have been found to date. Systematic DNA sequencing of <italic>GLRB</italic> in individuals with hyperekplexia revealed new missense mutations in <italic>GLRB</italic>, resulting in M177R, L285R and W310C substitutions. The recessive mutation M177R results in the insertion of a positively-charged residue into a hydrophobic pocket in the extracellular domain, resulting in an increased EC<sub>50</sub> and decreased maximal responses of Î±<sub>1</sub>Î² GlyRs. The <italic>de novo</italic> mutation L285R results in the insertion of a positively-charged side chain into the pore-lining 9â² position. Mutations at this site are known to destabilize the channel closed state and produce spontaneously active channels. Consistent with this, we identified a leak conductance associated with spontaneous GlyR activity in cells expressing Î±<sub>1</sub>Î²<sup>L285R</sup> GlyRs. Peak currents were also reduced for Î±<sub>1</sub>Î²<sup>L285R</sup> GlyRs although glycine sensitivity was normal. W310C was predicted to interfere with hydrophobic side-chain stacking between M1, M2 and M3. We found that W310C had no effect on glycine sensitivity, but reduced maximal currents in Î±<sub>1</sub>Î² GlyRs in both homozygous (Î±<sub>1</sub>Î²<sup>W310C</sup>) and heterozygous (Î±<sub>1</sub>Î²Î²<sup>W310C</sup>) stoichiometries. Since mild startle symptoms were reported in W310C carriers, this may represent an example of incomplete dominance in startle disease, providing a potential genetic explanation for the âminorâ form of hyperekplexia.</p>
      </abstract>
      <abstract abstract-type="graphical">
        <title>Highlights</title>
        <p>âº We report novel missense mutations in the GlyR Î² subunit gene causing startle disease. âº Mutation M177R in the extracellular domain decreases GlyR agonist affinity. âº Mutation L285R in TM2 produces spontaneously active channels. âº Mutation W310C in TM3 affects hydrophobic stacking and shows incomplete dominance. âº Mutations in <italic>GLRB</italic> have unique pathogenic mechanisms and modes of inheritance.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>
          <italic>GLRA1</italic>
        </kwd>
        <kwd>
          <italic>GLRB</italic>
        </kwd>
        <kwd>Glycine receptor</kwd>
        <kwd>Hyperekplexia</kwd>
        <kwd>Startle disease</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s0005">
      <title>Introduction</title>
      <p>Inhibitory glycine receptors (GlyRs) are ligand-gated chloride channels enriched in the spinal cord, brainstem and retina, consisting of heteropentameric combinations of ligand-binding GlyR Î± subunits (Î±<sub>1</sub>âÎ±<sub>4</sub>) together with the GlyR Î² subunit (<xref rid="bb0175" ref-type="bibr">Lynch, 2009</xref>). Each GlyR subunit is composed of an N-terminal extracellular domain and four Î±-helical membrane-spanning domains (M1âM4). M3 and M4 are linked by a long intracellular domain containing binding sites for a variety of intracellular factors. Although GlyR Î± and Î² subunits both play an active role in agonist binding (<xref rid="bb0075 bb0100" ref-type="bibr">Dutertre et al., 2012; Grudzinska et al., 2005</xref>), the GlyR Î² subunit was, until recently, widely assumed to play solely a structural role in heteromeric GlyRs. In part, this was due to the key role of the GlyR Î² subunit in mediating high-affinity interactions with the synaptic clustering molecule gephyrin (<xref rid="bb0185" ref-type="bibr">Meyer et al., 1995</xref>), which in turn controls the dynamic localization of GlyRs at synaptic sites (<xref rid="bb0090" ref-type="bibr">Feng et al., 1998</xref>). More recently, the GlyR Î² subunit was also reported to interact with the proteins Vacuolar Protein Sorting 35 (Vps35) and Neurobeachin (Nbea), indicating a new role in GlyR trafficking (<xref rid="bb0065" ref-type="bibr">del Pino et al., 2011</xref>). However, the atypical M2 domain of the GlyR Î² subunit also confers resistance to the effects of picrotoxinin (<xref rid="bb0220" ref-type="bibr">Pribilla et al., 1994</xref>) and the insecticide lindane (<xref rid="bb0130" ref-type="bibr">Islam and Lynch, 2012</xref>) as well as influencing the main-state single-channel conductances of heteromeric Î±Î² GlyRs (<xref rid="bb0025" ref-type="bibr">Bormann et al., 1993</xref>).</p>
      <p>Initial cross-linking studies of affinity-purified native GlyRs suggested that heteromeric GlyRs exist in a 3Î±:2Î² subunit combination (<xref rid="bb0160" ref-type="bibr">Langosch et al., 1988</xref>). However, three innovative studies have recently revealed that the GlyR Î² subunit represents the major component of heteromeric GlyRs, which are more likely to exist in a 2Î±:3Î² stoichiometry. <xref rid="bb0100" ref-type="bibr">Grudzinska et al., 2005</xref> compared the effects of mutations affecting predicted glycine binding residues in GlyR Î±<sub>1</sub> and Î² subunits. Co-expression of mutant GlyR Î±<sub>1</sub> with wild-type Î² subunits resulted in a full rescue of the EC<sub>50</sub> value for glycine, whilst co-expression of wild-type GlyR Î±<sub>1</sub> with mutant Î² subunits resulted in a decrease in EC<sub>50</sub>. A subsequent study (<xref rid="bb0075" ref-type="bibr">Dutertre et al., 2012</xref>) revealed that the GlyR Î² subunit contributes more to agonist binding site formation than had been previously realized. Experiments with GlyR Î±<sub>1</sub>-Î² subunit concatemers also revealed that functional heteromeric GlyRs can be produced when these were co-expressed with GlyR Î² subunit monomers but not when expressed alone, or with GlyR Î±<sub>1</sub> subunit monomers (<xref rid="bb0100" ref-type="bibr">Grudzinska et al., 2005</xref>). This result was consistent with either a 2Î±:3Î² or a 1Î±:4Î² stoichiometry. However, quantification of (<sup>35</sup>S)methionine incorporation into recombinant Î±<sub>1</sub>Î² versus Î±<sub>1</sub> subunit GlyRs suggested a 2Î±:3Î² stoichiometry and the subunit order Î²-Î±-Î²-Î±-Î². This stoichiometry and subunit arrangement has recently been confirmed by imaging single antibody-bound GlyR Î±<sub>1</sub>Î² heteromers using atomic force microscopy (<xref rid="bb0290" ref-type="bibr">Yang et al., 2012</xref>).</p>
      <p>Defects in the adult GlyR isoform (Î±<sub>1</sub>Î²) also have an important role in disease. Mutations in <italic>GLRA1</italic>, encoding the GlyR Î±<sub>1</sub> subunit, are the major genetic cause of startle disease/hyperekplexia in humans (<xref rid="bb0055 bb0255 bb0250" ref-type="bibr">Chung et al., 2010; Shiang et al., 1993, 1995</xref>) and cause similar disorders in mice (<xref rid="bb0030 bb0125 bb0235 bb0280" ref-type="bibr">Buckwalter et al., 1994; Holland et al., 2006; Ryan et al., 1994; Traka et al., 2006</xref>) and Poll Hereford cattle (<xref rid="bb0210" ref-type="bibr">Pierce et al., 2001</xref>). In humans, hyperekplexia affects newborn children and is characterized by exaggerated startle reflexes and hypertonia in response to sudden, unexpected auditory, tactile or visual stimuli. By contrast, <italic>GLRB</italic> mutations are less frequent, but recessive mutations have been discovered in three families with hyperekplexia (<xref rid="bb0010 bb0165 bb0230" ref-type="bibr">Al-Owain et al., 2012; Lee et al., 2012; Rees et al., 2002</xref>), in the mouse mutant <italic>spastic</italic> (<xref rid="bb0140 bb0195" ref-type="bibr">Kingsmore et al., 1994; MÃ¼lhardt et al., 1994</xref>) and the zebrafish <italic>bandoneon</italic> mutant (<xref rid="bb0300" ref-type="bibr">Hirata et al., 2005</xref>). However, one conundrum is why so few <italic>GLRB</italic> mutations are found in startle disease relative to <italic>GLRA1</italic>, or <italic>SLC6A5</italic>, encoding the presynaptic glycine transporter GlyT2, which are the primary and secondary genetic causes of startle disease respectively (<xref rid="bb0040 bb0095 bb0225" ref-type="bibr">Carta et al., 2012; GimÃ©nez et al., 2012; Rees et al., 2006</xref>). Here we report the characterization of three new missense mutations in <italic>GLRB</italic>, resulting in M177R, L285R and W310C substitutions in the extracellular domain, and the M2 and M3 membrane-spanning domains, respectively. We present detailed molecular modeling and functional analysis of these new GlyR Î² subunit mutations, revealing novel pathogenic mechanisms and modes of inheritance.</p>
    </sec>
    <sec sec-type="materials|methods" id="s0010">
      <title>Materials and methods</title>
      <sec id="s0025">
        <title>Patients and cases</title>
        <p>49 individuals with a clinical diagnosis of hyperekplexia (non-habituating startle response, positive nose tap test, history of neonatal/infantile hypertonicity) but lacking mutations in <italic>GLRA1</italic> and <italic>SLC6A5</italic> were ascertained by referral from pediatricians from international centers. DNA analysis of <italic>GLRB</italic> was performed at the Laboratory for Diagnostic Genome Analysis (LDGA) of the Center of Human and Clinical Genetics of the Leiden University Medical Center. The LDGA is NEN-EN-ISO 15189:2007 accredited by the Dutch Accreditation Council. Informed consent for participation in the study and publication of clinical and genetic data was obtained by the referring clinicians (MV at Sahlgrenska University Hospital and FMC at Imperial College London).</p>
      </sec>
      <sec id="s0030">
        <title>Genetic analysis</title>
        <p>DNA was extracted from whole blood taken from affected individuals and relatives using a Gentra Puregene DNA purification Kit (Gentra Systems, Minneapolis, USA). Primers recognizing the ten <italic>GLRB</italic> coding exons and flanking splice sites were designed using the Lightscanner Primer Design Software package, version 1 (Idaho Technology Inc, Salt Lake City, Utah). To avoid allelic dropout, all primers were placed in intronic regions that were devoid of single-nucleotide polymorphisms (SNPs) as revealed by National Center for Biotechnology Information databases. Primer designs are provided in <xref rid="ec0005" ref-type="supplementary-material">Supplementary tableÂ 1</xref>. Amplified PCR fragments were sequenced on an ABI PRISM 3730 using the BigDye Terminator cycle sequencing ready reaction kit (Applied Biosystems, Foster City, CA, USA) and analyzed using SeqScap software for comparative sequence analysis (Applied Biosystems). Single nucleotide variants (SNVs) were assessed against those found in NCBI dbSNP Build 136 and release 20100804 from the 1000 genomes project.</p>
      </sec>
      <sec id="s0035">
        <title>Homology modeling of the human GlyR</title>
        <p>Fold recognition of human GlyR Î±<sub>1</sub> and Î² subunits was performed with HHPred (<xref rid="bb0260" ref-type="bibr">SÃ¶ding et al., 2005</xref>), identifying the structure of the <italic>Caenorhabditis elegans</italic> glutamate-gated chloride channel (GluCl; PDB: <ext-link ext-link-type="uri" xlink:href="pdb:3RHW">3RHW</ext-link>) (<xref rid="bb0110" ref-type="bibr">Hibbs and Gouaux, 2011</xref>) as the best template (p-value: 0). A profileâprofile alignment between the human GlyR Î±<sub>1</sub> subunit and the GluCl Î± subunit was generated using MUSCLE (<xref rid="bb0080" ref-type="bibr">Edgar, 2004</xref>) and T-COFFEE (<xref rid="bb0200" ref-type="bibr">Notredame et al., 2000</xref>) resulting in 44.4% sequence identity. A separate alignment was generated for the human GlyR Î² subunit and GluCl resulting in 38.9% sequence identity. A short part of the sequence at the N-terminus of the Î² subunit (residues 1â30), and the extended loop region between M3 and M4 of both the Î±<sub>1</sub> and Î² subunits (residues 312â396 and 337â453, respectively) could not be accurately modeled due to lack of sequence identity and were therefore removed. The two alignments were inspected manually and combined to include all five subunits together to re-create the entire pentameric structure in the stoichiometry 2Î±<sub>1</sub>:3Î² with the subunit arrangement Î²-Î±-Î²-Î±-Î². Using MODELLER-9v10 (<xref rid="bb0085" ref-type="bibr">Eswar et al., 2003</xref>), 50 models were built based on the combined alignment, restraining disulfide bonds between the cysteine residues involved in the cys-loops within each subunit (C138âC152 and C198âC209 in the Î±<sub>1</sub> subunit and C161âC175 and C221âC233 in the Î² subunit). Each model was assessed by MODELLER with the Discrete Optimized Protein Energy (DOPE) statistical potential score (<xref rid="bb0245" ref-type="bibr">Shen and Sali, 2006</xref>) and the optimal model was selected based on the lowest score (normalized DOPE Z score: âÂ 0.222). A further assessment of model quality was performed using QMEAN (<xref rid="bb0015" ref-type="bibr">Benkert et al., 2011</xref>) The QMEAN Z score for the human GlyR Î±<sub>1</sub>Î² model was âÂ 3.43, indicating a reasonable model (<xref rid="bb0015" ref-type="bibr">Benkert et al., 2011</xref>). Selected non-synonymous substitutions were modeled into the GlyR homology model with the <italic>swapaa</italic> command in Chimera (<xref rid="bb0205" ref-type="bibr">Pettersen et al., 2004</xref>) using the Dunbrack backbone-dependent rotamer library (<xref rid="bb0070" ref-type="bibr">Dunbrack, 2002</xref>) and taking into account the lowest clash score, highest number of H-bonds and highest rotamer probability.</p>
      </sec>
      <sec id="s0040">
        <title>Site-directed mutagenesis and expression constructs</title>
        <p>Full-length human GlyR Î±<sub>1</sub> and Î² subunits were cloned into the vector pRK5 as previously described (<xref rid="bb0055" ref-type="bibr">Chung et al., 2010</xref>). Mutations were introduced into pRK5-hGlyRÎ² using the QuikChange site-directed mutagenesis kit (Agilent). All expression constructs were confirmed by Sanger sequencing of the entire coding region.</p>
      </sec>
      <sec id="s0045">
        <title>Cell surface biotinylation assays</title>
        <p>Wild-type or mutant GlyR Î±<sub>1</sub>Î² heteromers were transiently-expressed in human embryonic kidney (HEK293) cells transfected using magnetofection (CombiMag: OZ Biosciences, Lipofectamine 2000; Invitrogen). GlyR Î±<sub>1</sub> and Î² subunit expression constructs were transfected at a DNA ratio of 1:10 to promote the formation of heteromeric Î±<sub>1</sub>Î² GlyRs. 32Â h after transfection, cell surface-expression of GlyR Î² subunits was measured using a cell membrane-impermeable reagent Sulfo-NHS-LC-Biotin (Pierce Biotechnology) as previously described (<xref rid="bb0055" ref-type="bibr">Chung et al., 2010</xref>). Proteins in the whole-cell lysates or cell-surface proteins were analyzed by Western blotting with an antibody against the GlyR Î² subunit (1:90; AbCam ab123886). An anti Î²-actin antibody (1:5000; AbCam) was used as a control to confirm that intracellular proteins were not labeled with biotin. The intensity of the immunoreactivity signal was quantified using ImageJ (<ext-link ext-link-type="uri" xlink:href="http://rsbweb.nih.gov/ij/">http://rsbweb.nih.gov/ij/</ext-link>).</p>
      </sec>
      <sec id="s0050">
        <title>Fluorescence-based imaging</title>
        <p>Cells were imaged using an automated fluorescence-based screening system using EYFP<sup>I152L</sup> fluorescence quench as an indicator of anion influx. In this technique, iodide flowing into the cell binds to and quenches EYFP<sup>I152L</sup> fluorescence, thus providing an indication of the relative activity levels of membrane anion channels (<xref rid="bb0150" ref-type="bibr">Kruger et al., 2005</xref>). Briefly, HEK AD293 cells were transfected with the plasmid DNAs for wild-type and mutant GlyRs and with the DNA for EYFP<sup>I152L</sup> as described in the results and plated into a 384-well plate. Unless otherwise indicated, all GlyR plasmid DNAs were transfected in equimolar ratios for both the fluorescence and patch-clamp electrophysiological assays. Within the following 24â32Â h, the culture medium in the wells was replaced with extracellular solution (140Â mM NaCl, 5Â mM KCl, 2Â mM CaCl<sub>2</sub>, 1Â mM MgCl<sub>2</sub>, 10Â mM HEPES, and 10Â mM glucose, pH 7.4 using NaOH). After 30Â min, fluorescence images of each well were obtained twice, before and after the application of NaI solution (140Â mM NaI, 5Â mM KCl, 2Â mM CaCl<sub>2</sub>, 1Â mM MgCl<sub>2</sub>, 10Â mM HEPES, and 10Â mM glucose, pHÂ 7.4 using NaOH) containing varying concentrations of glycine. Values were pooled from 3 to 4 experiments with three wells each containing &gt;Â 200 cells. To determine the glycine doseâresponse curve, an empirical three or four parameter Hill equation was fitted by a non-linear least squares algorithm using SigmaPlot 11.0 software. Throughout this study, â% quenchâ is defined as the (initial fluorescenceÂ âÂ final fluorescence)Â ÃÂ 100Â /Â initial fluorescence. Thus, a treatment that completely abolished all fluorescence would yield a 100% quench.</p>
      </sec>
      <sec id="s0055">
        <title>Electrophysiology</title>
        <p>Glycine-gated currents were measured using whole-cell patch-clamp electrophysiology at a holding potential of âÂ 40Â mV. Spontaneous single-channel currents were recorded from outside-out excised patches, held at âÂ 70Â mV and in the absence of agonist. HEK AD293 cells were transiently transfected with GlyR subunit expression constructs and plated on coverslips. Cells were continually superfused with extracellular solution (composition as above) and visualized with an inverted fluorescence microscope. Transfected cells were identified by co-transfection with an EGFP expression construct. Patch pipettes were pulled to final tip resistances of 1â4Â MÎ© (whole-cell) and 6â12Â MÎ© (outside-out) when filled with a standard intracellular solution (145Â mM CsCl, 2Â mM CaCl<sub>2</sub>, 2Â mM MgCl<sub>2</sub>, 10Â mM HEPES, 10Â mM EGTA, pH 7.4 with CsOH). Whole-cell currents, which were filtered at 1Â kHz and digitized at 2Â kHz, were recorded using an Axon MultiClamp 700B amplifier and pClamp10.2 software. Single-channel currents, which were filtered at 5Â kHz and digitized at 20Â kHz, were recorded using an Axon Axopatch 200B and pClamp10.2 software. Drugs diluted in extracellular solution were applied to cells or patches via gravity-forced perfusion using parallel small tubes. Solution exchange was complete within 200Â ms.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s0015">
      <title>Results</title>
      <sec id="s0060">
        <title>Mutation analysis of GLRB in hyperekplexia</title>
        <p>Individuals with startle disease lacking mutations in <italic>GLRA1</italic> and <italic>SLC6A5</italic> were screened for genetic variation in <italic>GLRB</italic> coding exons and donor and acceptor splice junctions by Sanger DNA sequencing. Sequence variants were assigned as potentially pathogenic after cross-referencing with known <italic>GLRB</italic> mutations and common <italic>GLRB</italic> polymorphisms found in dbSNP and the 1000 genomes project. This analysis revealed two novel sequence variants in <italic>GLRB</italic> (<xref rid="f0005" ref-type="fig">Fig.Â 1</xref>A, B, <xref rid="t0005" ref-type="table">TableÂ 1</xref>) in two individuals. Individual 1 harbored a two base missense mutation (c.920_921ÎinsGA) resulting in a L285R substitution in the second membrane-spanning domain (M2) of the GlyR Î² subunit. Since this change was found in the heterozygous state (<xref rid="f0005" ref-type="fig">Fig.Â 1</xref>A, B) and neither parent carries the mutation, this mutation appears to be <italic>de novo</italic>. By contrast, individual 2 harbored a different missense mutation (c.G996T), resulting in a W310C substitution in the third membrane-spanning domain (M3) of the GlyR Î² subunit. At first glance, this mutation appeared to show recessive inheritance, since both parents were heterozygous carriers. However, clinical assessments and functional data suggest an alternative mechanism of inheritance for this mutation (see below). Recently, another recessive mutation c.T596G, resulting in a M177R substitution, was reported (<xref rid="bb0010" ref-type="bibr">Al-Owain et al., 2012</xref>) in nine patients in a large family of Saudi Arabian origin with hyperekplexia and esotropia, an eye misalignment disorder where one or both eyes turn inward.</p>
      </sec>
      <sec id="s0065">
        <title>Clinical assessment</title>
        <p>Individual 1 is a male of white British descent born at term plus 11Â days. His weight and height were on the 3rd centile at delivery. Apneas were observed within 40Â min and hypertonia presented within the first hour after birth. These symptoms were severe enough to necessitate intubation, his rigidity made ventilation very difficult and startle was prominent during this time. The classical nose-tap reflex was also present. Magnetic resonance imaging (MRI) revealed subtle brain abnormalities, including a mild increase in signal on T2-weighted sequences in the white matter and obvious dentate nuclei; however the basal ganglia had an unremarkable appearance. At 3Â months of age stereotyped but unusual dystonic posturing movements were observed, including an arm-raising phenomenon that was followed by a period of generalized hypertonia during which voluntary movements were impossible. At 9Â months, his gross motor performance was at the level of 7Â months. Although this had broadly normalized by 14Â months, dystonic movements were still prominent. Minor motor delay remained a feature for some time and when last seen he was still hypereflexic and had prominent cervical hypertonia, although exaggerated startle was less prominent; he also had an alternating strabismus. Now at 9Â years, he remains small for his age. He still has very mild motor delay, but stiffness is not noticeable and he plays football regularly. He is making good progress in school and socially. He is mildly myopic but no longer has strabismus. No epileptic seizures have been observed.</p>
        <p>Individual 2 is a female of Turkish origin with consanguineous parents. She exhibited neonatal hypertonia and irregular breathing necessitating continuous positive airway pressure (CPAP) treatment for several days following birth. In addition, she had episodes of neonatal bradycardia and an excessive startle reflex, although consciousness was unaltered during startle episodes. She had a short period of generalized stiffness following the startle response during which voluntary movements were impossible. MRI imaging performed at 2Â months of age showed bilateral periventricular cystic changes, in keeping with periventricular leucomalacia (necrosis of white matter). She was not dysmorphic and is not currently of small stature, at only âÂ 1 SD below the mean. At 4Â months of age she had screaming periods without a clear loss of consciousness. Concurrently, she had spasms in the jaw and unusual movements of her arms. At that time her EEG was normal without focal signs. At 16Â months of age she had an abnormal EEG with clear high-amplitude spike and wave activity and occasional hypsarrythmia (high amplitude and irregular waves and spikes in a background of chaotic and disorganized activity). She was treated with nitrazepam and both the seizures and EEG changes disappeared. She currently takes clonazepam and has no further symptoms. She does not have gaze palsy, eye movement disorders, nor any apparent learning difficulties. According to the family her parents and maternal uncle had âlight symptomsâ in early life. However, further details of their early childhood have been lost over time and bound up within cultural restrictions surrounding disclosure. Her older sister (untested) has clear symptoms and her younger brother born in 2010 (tested) is also affected. The parents (both heterozygous for W310C) do not currently show any hyperekplexia symptoms.</p>
      </sec>
      <sec id="s0070">
        <title>Molecular modeling</title>
        <p>M177R, L285R and W310C substitutions were predicted (<xref rid="t0005" ref-type="table">TableÂ 1</xref>) to be damaging or probably/possibly damaging using SIFT (<xref rid="bb0155" ref-type="bibr">Kumar et al., 2009</xref>) and Polyphen-2 (<xref rid="bb0005" ref-type="bibr">Adzhubei et al., 2010</xref>), respectively. These bioinformatics tools predict the possible impact of an amino acid substitution on the structure using the conservation of amino acid residues in sequence alignments derived from related sequences and machine learning approaches. To gain further insights into the potential pathogenic mechanisms of these mutations, we constructed a homology model of the human Î±<sub>1</sub>Î² GlyR based on the crystal structure of the GluCl Î± subunit from <italic>C. elegans</italic> (<xref rid="bb0110" ref-type="bibr">Hibbs and Gouaux, 2011</xref>). The GluCl structure makes a significantly better template for homology modeling of the human GlyR compared to other ligand-gated ion channel structures such as <italic>Gloeobacter violaceus</italic> GLIC (<xref rid="bb0020" ref-type="bibr">Bocquet et al., 2009</xref>), <italic>Erwinia chrysanthemi</italic> ELIC (<xref rid="bb0115" ref-type="bibr">Hilf and Dutzler, 2009</xref>) or the <italic>Torpedo marmorata</italic> nAChR (<xref rid="bb0285" ref-type="bibr">Unwin, 2005</xref>) due to functional similarity (i.e. GluCl is an anion channel) and higher overall sequence identity. Profileâprofile alignment between the human GlyR subunits and the GluCl Î± subunit generated using MUSCLE (<xref rid="bb0080" ref-type="bibr">Edgar, 2004</xref>) and T-COFFEE (<xref rid="bb0200" ref-type="bibr">Notredame et al., 2000</xref>) resulted in 44.4% (Î±<sub>1</sub>) and 38.9% (Î²) identity. By contrast, GlyR subunits share lower sequence identity with GLIC (Î±<sub>1</sub>: 21.8% and Î²: 24.6%) and different nAChR subunits (Î±<sub>1</sub>: 19.7 to 20% and Î²: 23.9 to 24.6%). Our GlyR model (<xref rid="f0010" ref-type="fig">Fig.Â 2</xref>A) predicts that L285 in the GlyR Î² subunit is a pore-lining residue, projecting a small uncharged, hydrophobic side chain into the ion-channel lumen (<xref rid="f0010" ref-type="fig">Fig.Â 2</xref>B). The L285R mutation introduces a significantly larger, positively-charged side chain that projects into the pore lumen (<xref rid="f0010" ref-type="fig">Fig.Â 2</xref>C). Because this mutation is <italic>de novo</italic> and the individual is heterozygous for L285R, in theory heteromeric GlyRs could be formed <italic>in vivo</italic> containing 3Â ÃÂ wild-type, 1Ã, 2Â Ã or 3Â Ã mutant GlyR Î² subunits (<xref rid="f0010" ref-type="fig">Fig.Â 2</xref>C). Modeling of pore-lining residues at a Î² subunit/Î² subunit interface (<xref rid="f0015" ref-type="fig">Fig.Â 3</xref>A, B) reveals that L285 is at the 9â² position in M2, equivalent to L254 in GluCl. This mutation is predicted to disrupt the pentameric radial symmetry of the 9â² leucine âhydrophobic girdleâ, that is essential for stabilizing the pore in the closed channel state. Disruption of this girdle is well known to induce spontaneous channel activity and/or enhance agonist sensitivity in other Cys-loop receptors (<xref rid="bb0045 bb0050" ref-type="bibr">Chang and Weiss, 1998, 1999</xref>). In common with GluCl, none of the major pore-lining residues are charged, with the exception of D271 at the -5â² position at the cytoplasmic end of M2 (<xref rid="f0015" ref-type="fig">Fig.Â 3</xref>A). This is consistent with different models of anion channel function which suggest that the positive electrostatic potential at the base of the pore arises from either: i) buried basic residues at the intracellular entrance of the pore (<xref rid="bb0060" ref-type="bibr">Cymes and Grosman, 2011</xref>), such as R276 in the M2 0â² position in the GlyR Î² subunit (R252 in the GlyR Î±<sub>1</sub> subunit) or ii) oriented peptide dipoles in the M2 Î± helices (<xref rid="bb0110" ref-type="bibr">Hibbs and Gouaux, 2011</xref>). Given that the electrostatic potential at the 0â² position strongly influences single-channel conductance (<xref rid="bb0045 bb0050" ref-type="bibr">Chang and Weiss, 1998, 1999</xref>), it is possible that the introduction of a large, positively-charged residue at the 9â² position could have a similar effect.</p>
        <p>By contrast, the side-chain of W310 in M3 is part of an intramembrane network of aromatic residues (phenylalanine, tyrosine, histidine and tryptophan) contributed by M1, M3 and M4 (<xref rid="f0020" ref-type="fig">Fig.Â 4</xref>A, B). Substitution W310C introduces a significantly smaller and shorter side chain into this position (<xref rid="f0020" ref-type="fig">Fig.Â 4</xref>C), with a reactive sulfhydryl group. Although we considered that C310 might form a disulfide bond with C314 in M3, one turn down the helix in our model, the distance between the two sulfur atoms (4.6Â Ã) precludes this interaction (<xref rid="bb0295" ref-type="bibr">Careaga and Falke, 1992</xref>). In addition, disulfide bonds rarely form within the membrane or a reducing intracellular environment. Rather, our modeling predicts that the W310C substitution disrupts aromatic stacking (<xref rid="f0020" ref-type="fig">Fig.Â 4</xref>B) â a key requirement for correct GlyR assembly and cell-surface trafficking (<xref rid="bb0105" ref-type="bibr">Haeger et al., 2010</xref>).</p>
        <p>M177 is a hydrophobic amino acid located in the GlyR extracellular domain on a Î²-sheet (Î²7). The side-chain of this residue forms part of a hydrophobic pocket (<xref rid="f0025" ref-type="fig">Fig.Â 5</xref><italic>A</italic>) that is conserved within the GluCl structure (<xref rid="bb0110" ref-type="bibr">Hibbs and Gouaux, 2011</xref>), which has an isoleucine at the equivalent position. The M177R substitution results in the introduction of a positively-charged, hydrophilic side chain into this pocket (<xref rid="f0025" ref-type="fig">Fig.Â 5</xref>B), which is predicted to have a significant effect on the folding of the extracellular domain. Although M177/R177 are not predicted to directly influence glycine binding (<xref rid="f0025" ref-type="fig">Fig.Â 5</xref>C, D), disruption of the local structure around M177 is predicted to cause an indirect effect on agonist binding or signal transduction. For example, M177 is located just five residues away from F182, which is involved in a cation-Ï interaction (<xref rid="bb0215" ref-type="bibr">Pless et al., 2008</xref>) with the amino group of glycine.</p>
      </sec>
      <sec id="s0075">
        <title>Cell-surface biotinylation assays</title>
        <p>To establish whether the GlyR Î² subunit mutants impaired cell-surface expression of GlyRs, we carried out cell-surface biotinylation assays for heteromeric Î±<sub>1</sub>Î² GlyRs (<xref rid="bb0055" ref-type="bibr">Chung et al., 2010</xref>), detecting Î²-subunit expression using a specific antibody. Note that in the absence of the GlyR Î±<sub>1</sub> subunit, the GlyR Î² subunit is not expressed at the cell surface in HEK293 cells, but is retained in the rough endoplasmic reticulum (<xref rid="bb0145" ref-type="bibr">Kirsch et al., 1995</xref>). The M177R, L285R and W310C mutant polypeptides were all detected at equivalent levels to the wild-type GlyR Î² subunit in total cell lysates, suggesting that they synthesized correctly and are not prone to rapid degradation (<xref rid="f0030" ref-type="fig">Fig.Â 6</xref><italic>A</italic>). However, quantification of the biotinylation of heteromeric cell-surface Î±<sub>1</sub>Î² GlyRs revealed significant decreases in cell-surface expression of Î±<sub>1</sub>Î²<sup>L285R</sup> and Î±<sub>1</sub>Î²<sup>W310C</sup> subunit GlyRs (<xref rid="f0030" ref-type="fig">Fig.Â 6</xref>A, B) to 27.3Â Â±Â 1.1% for L285R and 21.5Â Â±Â 8.3% for W310C of the level of wild-type Î±<sub>1</sub>Î² GlyRs. By contrast, Î±<sub>1</sub>Î²<sup>M177R</sup> GlyRs had a similar level of cell-surface expression (104Â Â±Â 2.2%) when compared to wild-type Î±<sub>1</sub>Î² GlyRs.</p>
      </sec>
      <sec id="s0080">
        <title>Functional analysis using EYFP Cl<sup>â</sup> sensors and electrophysiology</title>
        <p>HEK AD293 cells were co-transfected with expression constructs encoding the GlyR Î±<sub>1</sub> subunit together with each GlyR Î² subunit mutant. To reproduce the heterozygous state, GlyR Î±<sub>1</sub> was co-transfected with wild-type and mutant GlyR Î² subunits. We initially employed the EYFP assay (<xref rid="bb0055 bb0150" ref-type="bibr">Chung et al., 2010; Kruger et al., 2005</xref>) to provide an indication of the anion influx rate through the recombinant GlyRs. The advantage of this approach is that responses of large numbers of cells can be averaged, thus permitting the reliable quantitation of small changes in the current fluxing capacity of functional GlyRs. Glycine doseâresponse relationships (<xref rid="f0035" ref-type="fig">Fig.Â 7</xref>A, B) revealed that the maximal fluorescence quench was significantly reduced for Î±<sub>1</sub>Î²<sup>L285R</sup>, Î±<sub>1</sub>Î²Î²<sup>L285R</sup>, Î±<sub>1</sub>Î²<sup>W310C</sup> and Î±<sub>1</sub>Î²Î²<sup>W310C</sup> GlyRs relative to wild-type Î±<sub>1</sub>Î² GlyRs (<xref rid="f0035" ref-type="fig">Fig.Â 7</xref>C), suggesting that mutations L285R and W310C reduce anion flux rates in both the homozygous and heterozygous states. We also found that the reduction of Cl<sup>-</sup> flux was dependent on the ratio of wild-type GlyR Î±<sub>1</sub> subunit (the amount was held constant) to mutant GlyR Î² subunits (<xref rid="f0035" ref-type="fig">Fig.Â 7</xref>D), with significantly reduced Cl<sup>-</sup> flux observed with increasing levels of Î²<sup>W310C</sup> expression. Given that Î±<sub>1</sub>Î² GlyRs exist in an invariant 2Î±:3Î² stoichiometry (<xref rid="bb0290" ref-type="bibr">Yang et al., 2012</xref>), we infer that increasing the Î²<sup>W310C</sup>:Î±1 subunit ratio increases the proportion of heteromeric GlyRs, which in turn reduces functional GlyR expression. These data are consistent with our biotinylation assays, and suggest Î²<sup>W310C</sup> subunits prevent wild-type GlyR subunits from trafficking to the cell surface. EC<sub>50</sub> values for wild-type Î±<sub>1</sub>Î², Î±<sub>1</sub>Î²<sup>L285R</sup> and Î±<sub>1</sub>Î²<sup>W310C</sup> GlyRs were 5Â Â±Â 1, 4Â Â±Â 1, 13Â Â±Â 2Â Î¼M, respectively (<xref rid="t0010" ref-type="table">TableÂ 2</xref>), suggesting that the L285R and W310C mutations do not substantially alter the agonist sensitivity of recombinant Î±<sub>1</sub>Î² GlyRs reaching the cell surface.</p>
        <p>To test if the mutated Î² subunits incorporate into functional GlyRs, the pore blocker lindane was applied. Lindane potently inhibits homomeric Î± subunit GlyRs, but has almost no effect on heteromeric Î±Î² subunit GlyRs (<xref rid="bb0130" ref-type="bibr">Islam and Lynch, 2012</xref>). GlyRs containing Î²<sup>L285R</sup> or Î²<sup>W310C</sup> subunits exhibited a reduced sensitivity to lindane, indicating that receptors incorporating these mutant subunits are functionally expressed at the cell surface (<xref rid="f0035" ref-type="fig">Fig.Â 7</xref>E). Since artificial mutations at the 9â² position in GABA<sub>C</sub> and GABA<sub>A</sub>R subunits result in spontaneously-opening channels (<xref rid="bb0045 bb0050" ref-type="bibr">Chang and Weiss, 1998, 1999</xref>), we also investigated whether Î±<sub>1</sub>Î²<sup>L285R</sup> GlyRs showed this property, by quantifying the fluorescence change in the absence of glycine. Both Î±<sub>1</sub>Î²<sup>L285R</sup> and Î±<sub>1</sub>Î²Î²<sup>L285R</sup> GlyRs showed a significant increase in quench relative to heteromeric Î±<sub>1</sub>Î² GlyRs, which is suggestive of spontaneous activity (<xref rid="f0035" ref-type="fig">Fig.Â 7</xref>F). Even in the absence of glycine, the quench observed was &gt;Â 20%. By contrast, the quench observed in the absence of glycine for Î±<sub>1</sub>Î²<sup>W310C</sup> containing GlyRs was only slightly higher than for wild-type GlyRs, suggesting that these GlyRs do not show spontaneous gating. Averaged results obtained using the EYFP Cl<sup>â</sup> flux assay for L285R and W310C are summarized in <xref rid="t0010" ref-type="table">TableÂ 2</xref>.</p>
        <p>Electrophysiology was subsequently used to analyze the effects of the L285R and W310C mutations on GlyR function in greater detail. Doseâresponse relationships confirmed that the agonist sensitivity for GlyRs containing either mutated subunit did not change relative to wild-type Î±<sub>1</sub>Î² heteromers (<xref rid="f0040" ref-type="fig">Fig.Â 8</xref>A, B). As in the EYFP assays, the presence of the GlyR Î² subunit was confirmed by applying lindane (<xref rid="f0040" ref-type="fig">Fig.Â 8</xref>A). Spontaneous activity of Î±<sub>1</sub>Î²<sup>L285R</sup>-containing GlyRs could be inhibited by the pore-blocker picrotoxin (<xref rid="f0040" ref-type="fig">Fig.Â 8</xref>C). However, due to the resistance of heteromeric Î±<sub>1</sub>Î² GlyRs to picrotoxin (<xref rid="bb0220" ref-type="bibr">Pribilla et al., 1994</xref>), this inhibition was typically only about 100Â pA. Single-channel recordings in the absence of glycine confirmed the spontaneous activity of Î±<sub>1</sub>Î²<sup>L285R</sup> GlyRs (<xref rid="f0040" ref-type="fig">Fig.Â 8</xref>D). Averaged over four patches, mean open probability in the absence of applied glycine was 0.04Â Â±Â 0.01. The maximal unitary conductance level (denoted by Î³2 in <xref rid="f0040" ref-type="fig">Fig.Â 8</xref>D) was 49.4Â Â±Â 0.7Â pS with an additional sub-conductance level (Î³1) at 23.9Â Â±Â 0.3Â pS (both nÂ =Â 4 patches). The dominant 49Â pS level corresponds closely to that observed in wild-type Î±<sub>1</sub>Î² GlyRs (44Â pS) (<xref rid="bb0025" ref-type="bibr">Bormann et al., 1993</xref>), indicating that the L285R substitution does not affect single-channel conductance. To investigate the properties of Î±<sub>1</sub>Î²<sup>W310C</sup> GlyRs, whole-cell recordings were made from &gt;Â 200 EGFP-expressing cells that had been transfected with both Î±<sub>1</sub> and Î²<sup>W310C</sup> subunits in a 1:10 molar ratio. Only 20 of these cells expressed glycine-gated currents, with only two of the 20 expressing lindane-insensitive GlyRs, suggesting a predominance of Î±<sub>1</sub>Î²<sup>W310C</sup> GlyRs in the cell membrane. In both of these cells, the maximal current amplitude was significantly reduced relative to wild-type GlyRs (<xref rid="f0040" ref-type="fig">Fig.Â 8</xref>E), suggesting a reduction in either maximum open probability, single-channel conductance, and/or the number of functional channels expressed in the plasma membrane. Based on the biotinylation results, we can conclude that the reduced current amplitude is at least partly caused by reduced cell-surface expression. The properties of whole-cell currents mediated by Î±<sub>1</sub>Î²<sup>L285R</sup> and Î±<sub>1</sub>Î²<sup>W310C</sup> GlyRs are summarized in <xref rid="t0015" ref-type="table">TableÂ 3</xref>.</p>
        <p>The M177R mutant resulted in both a reduction of maximal fluorescence quench (<xref rid="f0045" ref-type="fig">Fig.Â 9</xref>A, B) and a rightward shift in the EC<sub>50</sub> value for glycine (<xref rid="f0045" ref-type="fig">Fig.Â 9</xref>A) from 17Â Â±Â 5Â Î¼M for wild-type Î±<sub>1</sub>Î² GlyRs to 45Â Â±Â 14Â Î¼M Î±<sub>1</sub>Î²Î²<sup>M177R</sup> and 64Â Â±Â 13Â Î¼M for Î±<sub>1</sub>Î²<sup>M177R</sup> GlyRs (<xref rid="t0020" ref-type="table">TableÂ 4</xref>). Heteromeric Î±<sub>1</sub>Î²<sup>M177R</sup> GlyRs exhibited a slightly reduced sensitivity to lindane (<xref rid="f0045" ref-type="fig">Fig.Â 9</xref>C). However, the reduced glycine sensitivity indicates that receptors incorporating the Î²<sup>M177R</sup> subunit are expressed at the cell surface. Using patch-clamp electrophysiology, we confirmed that the EC<sub>50</sub> value of Î±<sub>1</sub>Î²<sup>M177R</sup> GlyRs was significantly increased from 39Â Â±Â 4Â Î¼M for wild-type Î±<sub>1</sub>Î² GlyRs to 162Â Â±Â 3Â Î¼M for Î±<sub>1</sub>Î²<sup>M177R</sup> GlyRs (<xref rid="f0045" ref-type="fig">Fig.Â 9</xref>D, E) and that peak current magnitudes relative to wild-type Î±<sub>1</sub>Î² heteromers were significantly reduced (<xref rid="f0045" ref-type="fig">Fig.Â 9</xref>D, E, <xref rid="t0015" ref-type="table">TableÂ 3</xref>). We infer from these results that Î²<sup>M177R</sup> was incorporated efficiently into functional heteromeric GlyRs. However, incorporation of Î²<sup>M177R</sup> did not render GlyRs completely insensitive to lindane (<xref rid="f0045" ref-type="fig">Fig.Â 9</xref>E, inset).</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s0020">
      <title>Discussion</title>
      <p>This study reports the identification and functional characterization of novel mutations in the GlyR Î² subunit gene (<italic>GLRB</italic>) that reveal new pathogenic mechanisms underlying startle disease/hyperekplexia. We identified two new missense variants in <italic>GLRB</italic> causing L285R and W310C substitutions in membrane spanning domains M2 and M3. Using molecular modeling, cell-surface biotinylation assays, an EYFP-based anion flux assay and patch clamp electrophysiology, we were able to establish the likely pathogenic mechanisms for L285R and W310C, as well as a third mutation â M177R â recently reported (<xref rid="bb0010" ref-type="bibr">Al-Owain et al., 2012</xref>) in a large Saudi Arabian family with hyperekplexia. L285R is a <italic>de novo</italic> mutation, i.e. not found in either parent, which reduces peak current magnitude by reducing the cell-surface trafficking of GlyRs. Since the L285R substitution disrupts the integrity of the 9â² leucine hydrophobic girdle that stabilizes the channel closed state (<xref rid="bb0045 bb0050" ref-type="bibr">Chang and Weiss, 1998, 1999</xref>), it was perhaps inevitable that Î±<sub>1</sub>Î²<sup>L285R</sup> GlyRs were also associated with leak conductance indicating tonic channel opening. Since we recently described a dominant GlyR Î±<sub>1</sub> subunit mutation in the large extracellular domain (Y128C) with a leak conductance (<xref rid="bb0055" ref-type="bibr">Chung et al., 2010</xref>), this pathogenic mechanism is an emerging theme in startle disease. Introduction of the pore-lining 9â² arginine residues might also have been expected to affect unitary conductance (<xref rid="bb0060" ref-type="bibr">Cymes and Grosman, 2011</xref>). However, we found that the dominant maximum conductance level of Î±<sub>1</sub>Î²<sup>L285R</sup> GlyRs (49Â pS) was similar to that of Î±<sub>1</sub>Î² GlyRs (44Â pS) (<xref rid="bb0025" ref-type="bibr">Bormann et al., 1993</xref>).</p>
      <p>On first impressions, W310C also appeared to be a classical recessive hyperekplexia mutation, interfering with the formation of cell-surface GlyRs, rather than affecting glycine sensitivity. However, detailed analysis revealed both novel pathogenic mechanisms and mode of inheritance for this missense mutation. Molecular modeling revealed that W310 is a key residue involved in a hydrophobic stack formed by aromatic residues in M1, M3 and M4 that determines GlyR subunit stoichiometry (<xref rid="bb0105" ref-type="bibr">Haeger et al., 2010</xref>). The W310C substitution in M3 is predicted to act by destabilizing intramembrane packing of Î±-helices, a result that is in accord with our functional studies, which show compromised cell-surface expression of Î±<sub>1</sub>Î²<sup>W310C</sup> and Î±<sub>1</sub>Î²Î²<sup>W310C</sup> GlyRs and the formation of a significant proportion of GlyR Î±<sub>1</sub> subunit homomers even in the presence of a ten-fold excess of Î²<sup>W310C</sup>. However, we cannot rule out the possibility that reductions in channel open probability or single-channel conductance may also have contributed to the reduced current-carrying capacity of these mutant receptors. The inheritance of this mutation is of significant clinical interest, since mild startle symptoms were reported in both parents. This mutation is likely to represent a case of incomplete dominance, i.e. a mutation that has an intermediate effect in heterozygous carriers. This mechanism is supported by our functional data, since the maximal quench was significantly reduced for both Î±<sub>1</sub>Î²<sup>W310C</sup> and Î±<sub>1</sub>Î²Î²<sup>W310C</sup> GlyRs compared to wild-type Î±<sub>1</sub>Î² GlyRs. It is tempting to speculate that mutations such as W310C in <italic>GLRB</italic> might form the genetic basis for âminor startleâ, an excessive startle response in the absence of hypertonia. This phenomenon has been reported (<xref rid="bb0270 bb0265 bb0275" ref-type="bibr">Tijssen et al., 1995, 1996, 2002</xref>) in several hyperekplexia studies, but even though âmajorâ and âminorâ startle can occur together in the same family, the genetic basis remains unresolved and it has been assumed by some to be a ânormal but pronounced startle responseâ. Our study suggests that certain GlyR mutations may show incomplete dominance, providing a potential genetic explanation for mild startle in heterozygous carriers. This mild startle is predicted to be more common for <italic>GLRB</italic> mutations, since the likelihood of a heterozygous carrier being able to synthesize fully wild-type GlyRs with a 2Î±<sub>1</sub>:3Î² stoichiometry when carrying a defective <italic>GLRA1</italic> allele is 1 in 4, versus 1 in 8 for a defective <italic>GLRB</italic> allele.</p>
      <p>The remaining <italic>GLRB</italic> substitution we studied in detail was M177R, which both molecular modeling and functional studies suggest does not disrupt cell-surface trafficking, but interferes indirectly with agonist binding, by disrupting a local Î²-sheet fold in the large extracellular domain. M177 is located just five residues away from F182, which participates in a cation-Ï interaction with glycine (<xref rid="bb0215" ref-type="bibr">Pless et al., 2008</xref>). Thus, the pathogenic mechanism for M177R resembles that of a previously reported mutation G229D, which also displayed a reduced EC<sub>50</sub> for glycine (<xref rid="bb0230" ref-type="bibr">Rees et al., 2002</xref>).</p>
      <p>Our ongoing genetic screening program has recently revealed numerous recessive mutations in the genes encoding the GlyR Î±<sub>1</sub> subunit (<italic>GLRA1</italic>) and GlyT2 gene (<italic>SLC6A5</italic>). However, one conundrum is why so few <italic>GLRB</italic> mutations have been reported in startle disease. In part, this may be historical: <italic>GLRA1</italic> was the first startle disease gene to be discovered in 1993 (<xref rid="bb0255" ref-type="bibr">Shiang et al., 1993</xref>) and mutations in this gene explain the majority of cases of dominant hyperekplexia. By contrast, mutations in <italic>GLRB</italic> and <italic>SLC6A5</italic> were first reported in 2002 and 2006, respectively (<xref rid="bb0230 bb0225" ref-type="bibr">Rees et al., 2002, 2006</xref>). This âhead startâ for <italic>GLRA1</italic> is reflected in the NCBI gene-testing registry. Of the clinical laboratories world-wide offering screening for startle disease, seven screen for <italic>GLRA1</italic> mutations, three offer screening for <italic>GLRB</italic> and only one offers screening for <italic>SLC6A5</italic> mutations. However, this testing does not reflect the true prevalence of disease alleles â for example, we recently reported twenty new pathogenic sequence variants for GlyT2 in 17 index cases (<xref rid="bb0040" ref-type="bibr">Carta et al., 2012</xref>), as well as a new dominant GlyT2 mutation found in multiple families (<xref rid="bb0095" ref-type="bibr">GimÃ©nez et al., 2012</xref>). These studies certainly suggest that <italic>SLC6A5</italic> is a major startle disease gene. Methodology may also play a role: initial attempts at screening <italic>GLRB</italic> used single-strand conformation polymorphism (SSCP) or bi-directional di-deoxy fingerprinting (ddF) methods (<xref rid="bb0190 bb0230" ref-type="bibr">Milani et al., 1998; Rees et al., 2002</xref>), which have variable sensitivity for mutation detection. By contrast, our study and two other recent reports (<xref rid="bb0010 bb0165" ref-type="bibr">Al-Owain et al., 2012; Lee et al., 2012</xref>) have used Sanger DNA sequencing â currently the method of choice for mutation detection â although this is likely to be superseded in time by targeted next-generation sequencing panels (<xref rid="bb0170" ref-type="bibr">Lemke et al., 2012</xref>). The extended clinical phenotype in these cases, encompassing breathing difficulties/severe neonatal apnea episodes, bradycardia and developmental delay is likely to be explained by the loss of multiple synaptic GlyR subtypes <italic>in vivo</italic>, i.e. Î±<sub>2</sub>Î², Î±<sub>3</sub>Î² as well as the predominant Î±<sub>1</sub>Î² isoform. In this regard, it is noteworthy that GlyR Î±<sub>3</sub> subunit knockout mice were recently shown to have an irregular respiratory rhythm, due to loss of 5HT<sub>1A</sub>-mediated modulation of GlyRs in the brainstem (<xref rid="bb0180" ref-type="bibr">Manzke et al., 2010</xref>).</p>
      <p>It is also clear that there are key differences in the relative damage caused by equivalent missense changes in GlyR Î±<sub>1</sub> versus GlyR Î² subunits. For example, dominant startle disease mutations in <italic>GLRA1</italic> predominantly affect key amino acid residues in the M2 domain and M2-M3 linker region of the GlyR Î±<sub>1</sub> subunit (<xref rid="f0005" ref-type="fig">Fig.Â 1</xref><italic>A</italic>), where they act to uncouple ligand-binding from channel gating. <xref rid="bb0240" ref-type="bibr">Shan et al. (2011)</xref> recently demonstrated that GlyR function is less sensitive to hyperekplexia-mimicking mutations introduced into the M2âM3 loop of the GlyR Î² subunit than the Î±<sub>1</sub> subunit. This suggests that the GlyR Î±<sub>1</sub> M2âM3 loop dominates the Î² subunit in gating heteromeric Î±<sub>1</sub>Î² GlyRs and in turn that it is perhaps unlikely that a set of equivalent dominant mutations in the M2âM3 linker (<xref rid="f0005" ref-type="fig">Fig.Â 1</xref><italic>A</italic>) will be found in <italic>GLRB</italic>. This is consistent with our finding that GlyRs containing the L285R mutant exhibit an EC<sub>50</sub> that is similar to wild-type, confirming that the Î² subunit is not the major mediator of signal transduction in heteromeric GlyRs. Rather, the <italic>GLRB</italic> mutations found to date appear to cluster near key glycine binding residues (M177R, G229D) or are found in membrane-spanning domains M1âM3 (<xref rid="f0005" ref-type="fig">Fig.Â 1</xref>B), where they disrupt receptor trafficking and affect ion-channel function (L285R) or hydrophobic side-chain stacking (W310C).</p>
      <p>Other potential pathogenic mechanisms for <italic>GLRB</italic> include protein truncation (via deletion, frameshift, splice site or nonsense mutations) or mutations in the gephyrin-binding site located between M3 and M4 (<xref rid="f0005" ref-type="fig">Fig.Â 1</xref><italic>B</italic>). At least <italic>in vitro</italic>, artificial missense mutations affecting single amino acids, such as F398A in the GlyR Î² subunit gephyrin-binding motif are capable of significantly impairing GlyR Î²-gephyrin interactions (<xref rid="bb0135" ref-type="bibr">Kim et al., 2006</xref>), which would in turn abolish GlyR clustering at synapses. Based on our previous experience with <italic>GLRA1</italic> and <italic>SLC6A5</italic>, we consider it likely that a number of recessive SNVs remain to be discovered in <italic>GLRB</italic>. Based on the discovery of four new <italic>GLRB</italic> variants associated with hyperekplexia in this year alone (<xref rid="bb0010 bb0165" ref-type="bibr">Al-Owain et al., 2012; Lee et al., 2012</xref>, this study), we recommend that <italic>GLRB</italic> should have equal status alongside <italic>GLRA1</italic> and <italic>SLC6A5</italic> in the molecular genetic diagnosis of startle disease.</p>
      <p>The following are the supplementary data related to this article.<supplementary-material content-type="local-data" id="ec0005"><caption><title>Supplementary tableÂ 1</title><p>PCR primers for GLRB exon amplification.</p></caption><media xlink:href="mmc1.doc"/></supplementary-material></p>
    </sec>
    <sec id="s0085">
      <title>Competing interests</title>
      <p>All authors have declared that no competing interests exist.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bb0005">
        <element-citation publication-type="journal" id="rf0005">
          <person-group person-group-type="author">
            <name>
              <surname>Adzhubei</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Peshkin</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Ramensky</surname>
              <given-names>V.E.</given-names>
            </name>
            <name>
              <surname>Gerasimova</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bork</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>A method and server for predicting damaging missense mutations</article-title>
          <source>Nat. Methods</source>
          <volume>7</volume>
          <year>2010</year>
          <fpage>248</fpage>
          <lpage>249</lpage>
          <pub-id pub-id-type="pmid">20354512</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0010">
        <element-citation publication-type="journal" id="rf0010">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Owain</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Colak</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Al-Bakheet</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Al-Hashmi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Shuaib</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Al-Hemidan</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Novel mutation in <italic>GLRB</italic> in a large family with hereditary hyperekplexia</article-title>
          <source>Clin. Genet.</source>
          <volume>81</volume>
          <year>2012</year>
          <fpage>479</fpage>
          <lpage>484</lpage>
          <pub-id pub-id-type="pmid">21391991</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0015">
        <element-citation publication-type="journal" id="rf0015">
          <person-group person-group-type="author">
            <name>
              <surname>Benkert</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Biasini</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schwede</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Toward the estimation of the absolute quality of individual protein structure models</article-title>
          <source>Bioinformatics</source>
          <volume>27</volume>
          <year>2011</year>
          <fpage>343</fpage>
          <lpage>350</lpage>
          <pub-id pub-id-type="pmid">21134891</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0020">
        <element-citation publication-type="journal" id="rf0020">
          <person-group person-group-type="author">
            <name>
              <surname>Bocquet</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Nury</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Baaden</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Le Poupon</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Changeux</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Delarue</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation</article-title>
          <source>Nature</source>
          <volume>457</volume>
          <year>2009</year>
          <fpage>111</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="pmid">18987633</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0025">
        <element-citation publication-type="journal" id="rf0025">
          <person-group person-group-type="author">
            <name>
              <surname>Bormann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>RundstrÃ¶m</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Langosch</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Residues within transmembrane segment M2 determine chloride conductance of glycine receptor homo- and hetero-oligomers</article-title>
          <source>EMBO J.</source>
          <volume>12</volume>
          <year>1993</year>
          <fpage>3729</fpage>
          <lpage>3737</lpage>
          <pub-id pub-id-type="pmid">8404844</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0030">
        <element-citation publication-type="journal" id="rf0030">
          <person-group person-group-type="author">
            <name>
              <surname>Buckwalter</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Davisson</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>W.F.</given-names>
            </name>
            <name>
              <surname>Camper</surname>
              <given-names>S.A.</given-names>
            </name>
          </person-group>
          <article-title>A frameshift mutation in the mouse Î±1 glycine receptor gene (<italic>Glra1</italic>) results in progressive neurological symptoms and juvenile death</article-title>
          <source>Hum. Mol. Genet.</source>
          <volume>3</volume>
          <year>1994</year>
          <fpage>2025</fpage>
          <lpage>2030</lpage>
          <pub-id pub-id-type="pmid">7874121</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0295">
        <element-citation publication-type="journal" id="rf0285">
          <person-group person-group-type="author">
            <name>
              <surname>Careaga</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Falke</surname>
              <given-names>J.J.</given-names>
            </name>
          </person-group>
          <article-title>Thermal motions of surface Î±-helices in the D-galactose chemosensory receptor. Detection by disulfide trapping</article-title>
          <source>J. Mol. Biol.</source>
          <volume>226</volume>
          <year>1992</year>
          <fpage>1219</fpage>
          <lpage>1235</lpage>
          <pub-id pub-id-type="pmid">1518053</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0040">
        <element-citation publication-type="journal" id="rf0040">
          <person-group person-group-type="author">
            <name>
              <surname>Carta</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>James</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Remy</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in the GlyT2 gene (<italic>SLC6A5</italic>) are a second major cause of hyperekplexia</article-title>
          <source>J. Biol. Chem.</source>
          <volume>287</volume>
          <year>2012</year>
          <fpage>28975</fpage>
          <lpage>28985</lpage>
          <pub-id pub-id-type="pmid">22700964</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0045">
        <element-citation publication-type="journal" id="rf0045">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>D.S.</given-names>
            </name>
          </person-group>
          <article-title>Substitutions of the highly conserved M2 leucine create spontaneously opening Ï1 Î³-aminobutyric acid receptors</article-title>
          <source>Mol. Pharmacol.</source>
          <volume>53</volume>
          <year>1998</year>
          <fpage>511</fpage>
          <lpage>523</lpage>
          <pub-id pub-id-type="pmid">9495819</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0050">
        <element-citation publication-type="journal" id="rf0050">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>D.S.</given-names>
            </name>
          </person-group>
          <article-title>Allosteric activation mechanism of the Î±1Î²2Î³2 Î³-aminobutyric acid type A receptor revealed by mutation of the conserved M2 leucine</article-title>
          <source>Biophys. J.</source>
          <volume>77</volume>
          <year>1999</year>
          <fpage>2542</fpage>
          <lpage>2551</lpage>
          <pub-id pub-id-type="pmid">10545355</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0055">
        <element-citation publication-type="journal" id="rf0055">
          <person-group person-group-type="author">
            <name>
              <surname>Chung</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Vanbellinghen</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Mullins</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hantke</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hammond</surname>
              <given-names>C.L.</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiological mechanisms of dominant and recessive <italic>GLRA1</italic> mutations in hyperekplexia</article-title>
          <source>J. Neurosci.</source>
          <volume>30</volume>
          <year>2010</year>
          <fpage>9612</fpage>
          <lpage>9620</lpage>
          <pub-id pub-id-type="pmid">20631190</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0060">
        <element-citation publication-type="journal" id="rf0060">
          <person-group person-group-type="author">
            <name>
              <surname>Cymes</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Grosman</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Tunable pKa values and the basis of opposite charge selectivities in nicotinic-type receptors</article-title>
          <source>Nature</source>
          <volume>474</volume>
          <year>2011</year>
          <fpage>526</fpage>
          <lpage>530</lpage>
          <pub-id pub-id-type="pmid">21602825</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0065">
        <element-citation publication-type="journal" id="rf0065">
          <person-group person-group-type="author">
            <name>
              <surname>del Pino</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Paarmann</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Karas</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kilimann</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The trafficking proteins Vacuolar Protein Sorting 35 and Neurobeachin interact with the glycine receptor Î² subunit</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>412</volume>
          <year>2011</year>
          <fpage>435</fpage>
          <lpage>440</lpage>
          <pub-id pub-id-type="pmid">21821005</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0070">
        <element-citation publication-type="journal" id="rf0070">
          <person-group person-group-type="author">
            <name>
              <surname>Dunbrack</surname>
              <given-names>R.L.</given-names>
              <suffix>Jr.</suffix>
            </name>
          </person-group>
          <article-title>Rotamer libraries in the 21st century</article-title>
          <source>Curr. Opin. Struct. Biol.</source>
          <volume>12</volume>
          <year>2002</year>
          <fpage>431</fpage>
          <lpage>440</lpage>
          <pub-id pub-id-type="pmid">12163064</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0075">
        <element-citation publication-type="journal" id="rf0075">
          <person-group person-group-type="author">
            <name>
              <surname>Dutertre</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Drwal</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Laube</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Probing the pharmacological properties of distinct subunit interfaces within heteromeric glycine receptors reveals a functional Î²Î² agonist binding site</article-title>
          <source>J. Neurochem.</source>
          <volume>122</volume>
          <year>2012</year>
          <fpage>38</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="pmid">22486198</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0080">
        <element-citation publication-type="journal" id="rf0080">
          <person-group person-group-type="author">
            <name>
              <surname>Edgar</surname>
              <given-names>R.C.</given-names>
            </name>
          </person-group>
          <article-title>MUSCLE: multiple sequence alignment with high accuracy and high throughput</article-title>
          <source>Nucleic Acids Res.</source>
          <volume>32</volume>
          <year>2004</year>
          <fpage>1792</fpage>
          <lpage>1797</lpage>
          <pub-id pub-id-type="pmid">15034147</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0085">
        <element-citation publication-type="journal" id="rf0085">
          <person-group person-group-type="author">
            <name>
              <surname>Eswar</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>John</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Mirkovic</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Fiser</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ilyin</surname>
              <given-names>V.A.</given-names>
            </name>
            <name>
              <surname>Pieper</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Tools for comparative protein structure modeling and analysis</article-title>
          <source>Nucleic Acids Res.</source>
          <volume>31</volume>
          <year>2003</year>
          <fpage>3375</fpage>
          <lpage>3380</lpage>
          <pub-id pub-id-type="pmid">12824331</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0090">
        <element-citation publication-type="journal" id="rf0090">
          <person-group person-group-type="author">
            <name>
              <surname>Feng</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Tintrup</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kirsch</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Nichol</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Kuhse</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Dual requirement for gephyrin in glycine receptor clustering and molybdoenzyme activity</article-title>
          <source>Science</source>
          <volume>282</volume>
          <year>1998</year>
          <fpage>1321</fpage>
          <lpage>1324</lpage>
          <pub-id pub-id-type="pmid">9812897</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0095">
        <element-citation publication-type="journal" id="rf0095">
          <person-group person-group-type="author">
            <name>
              <surname>GimÃ©nez</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>PÃ©rez-Siles</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>MartÃ­nez-Villarreal</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Arribas-GonzÃ¡lez</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>JimÃ©nez</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>NÃºÃ±ez</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>A novel dominant hyperekplexia mutation Y705C alters trafficking and biochemical properties of the presynaptic glycine transporter GlyT2</article-title>
          <source>J. Biol. Chem.</source>
          <volume>287</volume>
          <year>2012</year>
          <fpage>28986</fpage>
          <lpage>29002</lpage>
          <pub-id pub-id-type="pmid">22753417</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0100">
        <element-citation publication-type="journal" id="rf0100">
          <person-group person-group-type="author">
            <name>
              <surname>Grudzinska</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Schemm</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Haeger</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nicke</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schmalzing</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The Î² subunit determines the ligand binding properties of synaptic glycine receptors</article-title>
          <source>Neuron</source>
          <volume>45</volume>
          <year>2005</year>
          <fpage>727</fpage>
          <lpage>739</lpage>
          <pub-id pub-id-type="pmid">15748848</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0105">
        <element-citation publication-type="journal" id="rf0105">
          <person-group person-group-type="author">
            <name>
              <surname>Haeger</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kuzmin</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Detro-Dassen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Kilb</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tsetlin</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>An intramembrane aromatic network determines pentameric assembly of Cys-loop receptors</article-title>
          <source>Nat. Struct. Mol. Biol.</source>
          <volume>17</volume>
          <year>2010</year>
          <fpage>90</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">20023641</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0110">
        <element-citation publication-type="journal" id="rf0110">
          <person-group person-group-type="author">
            <name>
              <surname>Hibbs</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Gouaux</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Principles of activation and permeation in an anion-selective Cys-loop receptor</article-title>
          <source>Nature</source>
          <volume>474</volume>
          <year>2011</year>
          <fpage>54</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">21572436</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0115">
        <element-citation publication-type="journal" id="rf0115">
          <person-group person-group-type="author">
            <name>
              <surname>Hilf</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Dutzler</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel</article-title>
          <source>Nature</source>
          <volume>457</volume>
          <year>2009</year>
          <fpage>115</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="pmid">18987630</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0300">
        <element-citation publication-type="journal" id="rf0290">
          <person-group person-group-type="author">
            <name>
              <surname>Hirata</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Saint-Amant</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Downes</surname>
              <given-names>G.B.</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Granato</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Zebrafish <italic>bandoneon</italic> mutants display behavioral defects due to a mutation in the glycine receptor Î²-subunit</article-title>
          <source>Proc. Natl. Acad. Sci. U. S. A.</source>
          <volume>102</volume>
          <year>2005</year>
          <fpage>8345</fpage>
          <lpage>8350</lpage>
          <pub-id pub-id-type="pmid">15928085</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0125">
        <element-citation publication-type="journal" id="rf0120">
          <person-group person-group-type="author">
            <name>
              <surname>Holland</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Fleming</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Cheek</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Moran</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Beier</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Meisler</surname>
              <given-names>M.H.</given-names>
            </name>
          </person-group>
          <article-title><italic>De novo</italic> exon duplication in a new allele of mouse <italic>Glra1</italic> (<italic>spasmodic</italic>)</article-title>
          <source>Genetics</source>
          <volume>174</volume>
          <year>2006</year>
          <fpage>2245</fpage>
          <lpage>2247</lpage>
          <pub-id pub-id-type="pmid">17028313</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0130">
        <element-citation publication-type="journal" id="rf0125">
          <person-group person-group-type="author">
            <name>
              <surname>Islam</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>Mechanism of action of the insecticides, lindane and fipronil, on glycine receptor chloride channels</article-title>
          <source>Br. J. Pharmacol.</source>
          <volume>165</volume>
          <year>2012</year>
          <fpage>2707</fpage>
          <lpage>2720</lpage>
          <pub-id pub-id-type="pmid">22035056</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0135">
        <element-citation publication-type="journal" id="rf0130">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>E.Y.</given-names>
            </name>
            <name>
              <surname>Schrader</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Smolinsky</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Bedet</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Vannier</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Deciphering the structural framework of glycine receptor anchoring by gephyrin</article-title>
          <source>EMBO J.</source>
          <volume>25</volume>
          <year>2006</year>
          <fpage>1385</fpage>
          <lpage>1395</lpage>
          <pub-id pub-id-type="pmid">16511563</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0140">
        <element-citation publication-type="journal" id="rf0135">
          <person-group person-group-type="author">
            <name>
              <surname>Kingsmore</surname>
              <given-names>S.F.</given-names>
            </name>
            <name>
              <surname>Giros</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Suh</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bieniarz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Caron</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Seldin</surname>
              <given-names>M.F.</given-names>
            </name>
          </person-group>
          <article-title>Glycine receptor Î²-subunit gene mutation in <italic>spastic</italic> mouse associated with LINE-1 element insertion</article-title>
          <source>Nat. Genet.</source>
          <volume>7</volume>
          <year>1994</year>
          <fpage>136</fpage>
          <lpage>141</lpage>
          <pub-id pub-id-type="pmid">7920630</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0145">
        <element-citation publication-type="journal" id="rf0140">
          <person-group person-group-type="author">
            <name>
              <surname>Kirsch</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kuhse</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Targeting of glycine receptor subunits to gephyrin-rich domains in transfected human embryonic kidney cells</article-title>
          <source>Mol. Cell. Neurosci.</source>
          <volume>6</volume>
          <year>1995</year>
          <fpage>450</fpage>
          <lpage>461</lpage>
          <pub-id pub-id-type="pmid">8581315</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0150">
        <element-citation publication-type="journal" id="rf0145">
          <person-group person-group-type="author">
            <name>
              <surname>Kruger</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hawthorne</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hryciw</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Frings</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Poronnik</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>A yellow fluorescent protein-based assay for high-throughput screening of glycine and GABA<sub>A</sub> receptor chloride channels</article-title>
          <source>Neurosci. Lett.</source>
          <volume>380</volume>
          <year>2005</year>
          <fpage>340</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="pmid">15862914</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0155">
        <element-citation publication-type="journal" id="rf0150">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Henikoff</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>P.C.</given-names>
            </name>
          </person-group>
          <article-title>Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm</article-title>
          <source>Nat. Protoc.</source>
          <volume>4</volume>
          <year>2009</year>
          <fpage>1073</fpage>
          <lpage>1081</lpage>
          <pub-id pub-id-type="pmid">19561590</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0160">
        <element-citation publication-type="journal" id="rf0155">
          <person-group person-group-type="author">
            <name>
              <surname>Langosch</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Conserved quaternary structure of ligand-gated ion channels: the postsynaptic glycine receptor is a pentamer</article-title>
          <source>Proc. Natl. Acad. Sci. U. S. A.</source>
          <volume>85</volume>
          <year>1988</year>
          <fpage>7394</fpage>
          <lpage>7398</lpage>
          <pub-id pub-id-type="pmid">2459705</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0165">
        <mixed-citation publication-type="other" id="or0010">Lee, C.G., Kwon, M.J., Yu, H.J., Nam, S.H., Lee, J., Ki, C.S. et al. 2012. Clinical features and genetic analysis of children with hyperekplexia in Korea. J. Child Neurol. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/0883073812">http://dx.doi.org/10.1177/0883073812</ext-link>.</mixed-citation>
      </ref>
      <ref id="bb0170">
        <element-citation publication-type="journal" id="rf0160">
          <person-group person-group-type="author">
            <name>
              <surname>Lemke</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Riesch</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Scheurenbrand</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Schubach</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wilhelm</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Targeted next generation sequencing as a diagnostic tool in epileptic disorders</article-title>
          <source>Epilepsia</source>
          <volume>53</volume>
          <year>2012</year>
          <fpage>1387</fpage>
          <lpage>1398</lpage>
          <pub-id pub-id-type="pmid">22612257</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0175">
        <element-citation publication-type="journal" id="rf0165">
          <person-group person-group-type="author">
            <name>
              <surname>Lynch</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>Native glycine receptor subtypes and their physiological roles</article-title>
          <source>Neuropharmacology</source>
          <volume>56</volume>
          <year>2009</year>
          <fpage>303</fpage>
          <lpage>309</lpage>
          <pub-id pub-id-type="pmid">18721822</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0180">
        <element-citation publication-type="journal" id="rf0170">
          <person-group person-group-type="author">
            <name>
              <surname>Manzke</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Niebert</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>U.R.</given-names>
            </name>
            <name>
              <surname>Caley</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Vogelgesang</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>HÃ¼lsmann</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ponimaskin</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>MÃ¼ller</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Smart</surname>
              <given-names>T.G.</given-names>
            </name>
            <name>
              <surname>Harvey</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Richter</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Serotonin receptor 1A-modulated phosphorylation of glycine receptor Î±3 controls breathing in mice</article-title>
          <source>J. Clin. Invest.</source>
          <volume>120</volume>
          <year>2010</year>
          <fpage>4118</fpage>
          <lpage>4128</lpage>
          <pub-id pub-id-type="pmid">20978350</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0185">
        <element-citation publication-type="journal" id="rf0175">
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kirsch</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Langosch</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Identification of a gephyrin binding motif on the glycine receptor Î² subunit</article-title>
          <source>Neuron</source>
          <volume>15</volume>
          <year>1995</year>
          <fpage>563</fpage>
          <lpage>572</lpage>
          <pub-id pub-id-type="pmid">7546736</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0190">
        <element-citation publication-type="journal" id="rf0180">
          <person-group person-group-type="author">
            <name>
              <surname>Milani</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>MÃ¼lhardt</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>R.G.</given-names>
            </name>
            <name>
              <surname>Lichter</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kioschis</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Poustka</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The human glycine receptor Î² subunit gene (<italic>GLRB</italic>): structure, refined chromosomal localization, and population polymorphism</article-title>
          <source>Genomics</source>
          <volume>50</volume>
          <year>1998</year>
          <fpage>341</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="pmid">9676428</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0195">
        <element-citation publication-type="journal" id="rf0185">
          <person-group person-group-type="author">
            <name>
              <surname>MÃ¼lhardt</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gass</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Simon-Chazottes</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>GuÃ©net</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Kuhse</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>The <italic>spastic</italic> mouse: aberrant splicing of glycine receptor Î² subunit mRNA caused by intronic insertion of L1 element</article-title>
          <source>Neuron</source>
          <volume>13</volume>
          <year>1994</year>
          <fpage>1003</fpage>
          <lpage>1015</lpage>
          <pub-id pub-id-type="pmid">7946325</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0200">
        <element-citation publication-type="journal" id="rf0190">
          <person-group person-group-type="author">
            <name>
              <surname>Notredame</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Heringa</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>T-COFFEE: a novel method for fast and accurate multiple sequence alignment</article-title>
          <source>J. Mol. Biol.</source>
          <volume>302</volume>
          <year>2000</year>
          <fpage>205</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="pmid">10964570</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0205">
        <element-citation publication-type="journal" id="rf0195">
          <person-group person-group-type="author">
            <name>
              <surname>Pettersen</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Goddard</surname>
              <given-names>T.D.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Couch</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Greenblatt</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>E.C.</given-names>
            </name>
          </person-group>
          <article-title>UCSF Chimera â a visualization system for exploratory research and analysis</article-title>
          <source>J. Comput. Chem.</source>
          <volume>25</volume>
          <year>2004</year>
          <fpage>1605</fpage>
          <lpage>1612</lpage>
          <pub-id pub-id-type="pmid">15264254</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0210">
        <element-citation publication-type="journal" id="rf0200">
          <person-group person-group-type="author">
            <name>
              <surname>Pierce</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Handford</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Vafa</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Dennis</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>A nonsense mutation in the Î±1 subunit of the inhibitory glycine receptor associated with bovine myoclonus</article-title>
          <source>Mol. Cell. Neurosci.</source>
          <volume>17</volume>
          <year>2001</year>
          <fpage>354</fpage>
          <lpage>363</lpage>
          <pub-id pub-id-type="pmid">11178872</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0215">
        <element-citation publication-type="journal" id="rf0205">
          <person-group person-group-type="author">
            <name>
              <surname>Pless</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Millen</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Hanek</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Lester</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Lummis</surname>
              <given-names>S.C.</given-names>
            </name>
          </person-group>
          <article-title>A cation-Ï interaction in the binding site of the glycine receptor is mediated by a phenylalanine residue</article-title>
          <source>J. Neurosci.</source>
          <volume>28</volume>
          <year>2008</year>
          <fpage>10937</fpage>
          <lpage>10942</lpage>
          <pub-id pub-id-type="pmid">18945901</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0220">
        <element-citation publication-type="journal" id="rf0210">
          <person-group person-group-type="author">
            <name>
              <surname>Pribilla</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Takagi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Langosch</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bormann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The atypical M2 segment of the Î² subunit confers picrotoxinin resistance to inhibitory glycine receptor channels</article-title>
          <source>EMBO J.</source>
          <volume>11</volume>
          <year>1994</year>
          <fpage>4305</fpage>
          <lpage>4311</lpage>
          <pub-id pub-id-type="pmid">1385113</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0225">
        <element-citation publication-type="journal" id="rf0215">
          <person-group person-group-type="author">
            <name>
              <surname>Rees</surname>
              <given-names>M.I.</given-names>
            </name>
            <name>
              <surname>Harvey</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Duguid</surname>
              <given-names>I.C.</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in the gene encoding GlyT2 (<italic>SLC6A5</italic>) define a presynaptic component of human startle disease</article-title>
          <source>Nat. Genet.</source>
          <volume>38</volume>
          <year>2006</year>
          <fpage>801</fpage>
          <lpage>806</lpage>
          <pub-id pub-id-type="pmid">16751771</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0230">
        <element-citation publication-type="journal" id="rf0220">
          <person-group person-group-type="author">
            <name>
              <surname>Rees</surname>
              <given-names>M.I.</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>T.M.</given-names>
            </name>
            <name>
              <surname>Kwok</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>Mortier</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Govaert</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Snell</surname>
              <given-names>R.G.</given-names>
            </name>
          </person-group>
          <article-title>Hyperekplexia associated with compound heterozygote mutations in the Î²-subunit of the human inhibitory glycine receptor (<italic>GLRB</italic>)</article-title>
          <source>Hum. Mol. Genet.</source>
          <volume>11</volume>
          <year>2002</year>
          <fpage>853</fpage>
          <lpage>860</lpage>
          <pub-id pub-id-type="pmid">11929858</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0235">
        <element-citation publication-type="journal" id="rf0225">
          <person-group person-group-type="author">
            <name>
              <surname>Ryan</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Buckwalter</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Handford</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Segura</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Shiang</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>A missense mutation in the gene encoding the Î±1 subunit of the inhibitory glycine receptor in the <italic>spasmodic</italic> mouse</article-title>
          <source>Nat. Genet.</source>
          <volume>7</volume>
          <year>1994</year>
          <fpage>131</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="pmid">7920629</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0240">
        <element-citation publication-type="journal" id="rf0295">
          <person-group person-group-type="author">
            <name>
              <surname>Shan</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>Î² subunit M2âM3 loop conformational changes are uncoupled from Î±1Î² glycine receptor channel gating: implications for human hereditary hyperekplexia</article-title>
          <source>PLoS One</source>
          <volume>6</volume>
          <year>2011</year>
          <fpage>e28105</fpage>
          <pub-id pub-id-type="pmid">22132222</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0245">
        <element-citation publication-type="journal" id="rf0235">
          <person-group person-group-type="author">
            <name>
              <surname>Shen</surname>
              <given-names>M.Y.</given-names>
            </name>
            <name>
              <surname>Sali</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Statistical potential for assessment and prediction of protein structures</article-title>
          <source>Protein Sci.</source>
          <volume>15</volume>
          <year>2006</year>
          <fpage>2507</fpage>
          <lpage>2524</lpage>
          <pub-id pub-id-type="pmid">17075131</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0250">
        <element-citation publication-type="journal" id="rf0240">
          <person-group person-group-type="author">
            <name>
              <surname>Shiang</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Y.Z.</given-names>
            </name>
            <name>
              <surname>Fielder</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Fryer</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Mutational analysis of familial and sporadic hyperekplexia</article-title>
          <source>Ann. Neurol.</source>
          <volume>38</volume>
          <year>1995</year>
          <fpage>85</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">7611730</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0255">
        <element-citation publication-type="journal" id="rf0245">
          <person-group person-group-type="author">
            <name>
              <surname>Shiang</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Y.Z.</given-names>
            </name>
            <name>
              <surname>Hahn</surname>
              <given-names>A.F.</given-names>
            </name>
            <name>
              <surname>O'Connell</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Wasmuth</surname>
              <given-names>J.J.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in the Î±1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia</article-title>
          <source>Nat. Genet.</source>
          <volume>5</volume>
          <year>1993</year>
          <fpage>351</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="pmid">8298642</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0260">
        <element-citation publication-type="journal" id="rf0250">
          <person-group person-group-type="author">
            <name>
              <surname>SÃ¶ding</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Biegert</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lupas</surname>
              <given-names>A.N.</given-names>
            </name>
          </person-group>
          <article-title>The HHpred interactive server for protein homology detection and structure prediction</article-title>
          <source>Nucleic Acids Res.</source>
          <volume>33</volume>
          <year>2005</year>
          <fpage>W244</fpage>
          <lpage>W248</lpage>
          <pub-id pub-id-type="pmid">15980461</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0265">
        <element-citation publication-type="journal" id="rf0255">
          <person-group person-group-type="author">
            <name>
              <surname>Tijssen</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Padberg</surname>
              <given-names>G.W.</given-names>
            </name>
            <name>
              <surname>van Dijk</surname>
              <given-names>J.G.</given-names>
            </name>
          </person-group>
          <article-title>The startle pattern in the minor form of hyperekplexia</article-title>
          <source>Arch. Neurol.</source>
          <volume>53</volume>
          <year>1996</year>
          <fpage>608</fpage>
          <lpage>613</lpage>
          <pub-id pub-id-type="pmid">8929168</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0270">
        <element-citation publication-type="journal" id="rf0260">
          <person-group person-group-type="author">
            <name>
              <surname>Tijssen</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Shiang</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>van Deutekom</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Boerman</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Wasmuth</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Sandkuijl</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>Molecular genetic reevaluation of the Dutch hyperekplexia family</article-title>
          <source>Arch. Neurol.</source>
          <volume>52</volume>
          <year>1995</year>
          <fpage>578</fpage>
          <lpage>582</lpage>
          <pub-id pub-id-type="pmid">7763205</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0275">
        <element-citation publication-type="journal" id="rf0265">
          <person-group person-group-type="author">
            <name>
              <surname>Tijssen</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Vergouwe</surname>
              <given-names>M.N.</given-names>
            </name>
            <name>
              <surname>van Dijk</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Rees</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Frants</surname>
              <given-names>R.R.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Major and minor form of hereditary hyperekplexia</article-title>
          <source>Mov. Disord.</source>
          <volume>17</volume>
          <year>2002</year>
          <fpage>826</fpage>
          <lpage>830</lpage>
          <pub-id pub-id-type="pmid">12210885</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0280">
        <element-citation publication-type="journal" id="rf0270">
          <person-group person-group-type="author">
            <name>
              <surname>Traka</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Seburn</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Popko</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title><italic>Nmf11</italic> is a novel ENU-induced mutation in the mouse glycine receptor Î±1 subunit</article-title>
          <source>Mamm. Genome</source>
          <volume>17</volume>
          <year>2006</year>
          <fpage>950</fpage>
          <lpage>955</lpage>
          <pub-id pub-id-type="pmid">16964444</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0285">
        <element-citation publication-type="journal" id="rf0275">
          <person-group person-group-type="author">
            <name>
              <surname>Unwin</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Refined structure of the nicotinic acetylcholine receptor at 4Â Ã resolution</article-title>
          <source>J. Mol. Biol.</source>
          <volume>346</volume>
          <year>2005</year>
          <fpage>967</fpage>
          <lpage>989</lpage>
          <pub-id pub-id-type="pmid">15701510</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0290">
        <element-citation publication-type="journal" id="rf0280">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Taran</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>T.I.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>Stoichiometry and subunit arrangement of Î±1Î² glycine receptors as determined by atomic force microscopy</article-title>
          <source>Biochemistry</source>
          <volume>51</volume>
          <year>2012</year>
          <fpage>5229</fpage>
          <lpage>5231</lpage>
          <pub-id pub-id-type="pmid">22715885</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack id="ac0005">
      <title>Acknowledgments</title>
      <p>This work was supported by the <funding-source id="gts0005">Medical Research Council</funding-source> (G0601585 to RJH, KH and MIR), <funding-source id="gts0010">Action Medical Research</funding-source> (1966 to RJH, RHT and MIR), a <funding-source id="gts0015">Bloomsbury Colleges</funding-source> studentship (to VMJ, MT and RJH), a <funding-source id="gts0020">MRC</funding-source> Career Development Award (G0600084 to MT), the <funding-source id="gts0025">National Institute of Social Care and Health Research</funding-source> (to MIR, RHT and SKC) and the <funding-source id="gts0030">National Health and Medical Research Council of Australia</funding-source> (to JWL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="f0005">
      <label>Fig.Â 1</label>
      <caption>
        <p>Human GlyR Î² subunit mutations identified in individuals with startle disease/hyperekplexia. Amino acid sequences of the human GlyR Î±<sub>1</sub> and Î² subunits indicating the positions of putative membrane-spanning domains (grey shaded boxes) defined by alignments with GluCl (<xref rid="bb0110" ref-type="bibr">Hibbs and Gouaux, 2011</xref>) and amino-acid residues affected by hyperekplexia mutations. Mutation key: dominant mutation: red; recessive: blue; <italic>de novo</italic>: orange. Green lettering denotes key ligand-binding residues in the GlyR Î±<sub>1</sub> and Î² subunits. Purple lettering denotes the gephyrin-binding motif between M3 and M4 of the GlyR Î² subunit.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="f0010">
      <label>Fig.Â 2</label>
      <caption>
        <p>Molecular modeling of the human Î±<sub>1</sub>Î² GlyR and mutation L285R. (A) Side view of the molecular model of the human GlyR Î±<sub>1</sub>Î² pentamer showing Î±<sub>1</sub> subunits in gold and Î² subunits in blue. The positions of the inner and outer membrane surfaces are indicated by grey spheres. (B) Orthographic view of the GlyR Î±<sub>1</sub>Î² pentamer, showing the relative position of the L285 side chain in the ion-channel pore. (C) Panels depicting the multiple GlyR isoforms that could be formed on co-expression of wild-type and mutant GlyR Î² subunits harboring the L285R substitution. A red plus sign denotes the positive charge carried by the side-chain of R285.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="f0015">
      <label>Fig.Â 3</label>
      <caption>
        <p>Mutation L285R inserts a charged residue into the GlyR ion-channel pore. (A) Sequence alignment of M2 of GluCl with GlyR Î±<sub>1</sub> and Î² subunits. Relative positions of residues that line the Cl<sup>â</sup> channel are indicated with black circles and residue numbers indicated for GluCl and the GlyR Î² subunit. Residues carrying presumed positive and negative charges are colored red and blue, respectively, although it should be noted that the protonation state of these residues at physiological pH has not been established. The position of L285 is indicated by grey highlighting. (B, C) Schematic diagrams depicting two GlyR Î² subunit M2 Î±-helices and residues lining the Cl<sup>â</sup> channel for wild-type L285 (B) and the R285 mutant (C). Blue spheres represent the predicted internal volume of the ion channel and side-chains are shown for pore-lining residues. The L285R substitution is predicted to create a premature narrowing of the pore at the 9â² position and inserts a positively charged residue (+) into an Î± helix that is uncharged, with the exception of D271 on the cytoplasmic face of the ion-channel pore.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="f0020">
      <label>Fig.Â 4</label>
      <caption>
        <p>Mutation W310C disrupts hydrophobic stacking of membrane-spanning domains M1âM3. (A) Cutaway view from the extracellular side of the GlyR Î² subunit showing how the side-chain of residue W310 in M3 contributes to a hydrophobic stack of aromatic residues contributed by membrane-spanning domains M1, M3 and M4. Hydrophobic side-chains of residues predicted to be involved in this stack are colored according to membrane-spanning domain: M1: red; M3: yellow and M4: blue. (B) Mutation W310C results in the loss of the aromatic, hydrophobic side chain of tryptophan and replacement with the shorter, reactive cysteine sulfydryl side chain. (CâF) Top and side views showing the hydrophobicity of individual residues in the stack by coloring the atom surfaces. Hydrophobic surfaces are depicted in orange, hydrophilic in blue and white indicates neutral polarity. The W310C substitution is predicted to disrupt the hydrophobic stack, altering the tertiary fold of the membrane-spanning domains and introduce an empty space (F, circled with a dashed line). Disulfide bond formation is unlikely, since this is rare within the membrane or an intracellular environment and the only adjacent sulfur atom (C314 in M3) is 6.4Â Ã away from C310 sulfur.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="f0025">
      <label>Fig.Â 5</label>
      <caption>
        <p>Mutation M177R disrupts local structure of a Î²-sheet in the N-terminal extracellular domain. (A, B) Side views of part of the GlyR Î² subunit extracellular domain showing the location of M177 (A) and R177 (B, red lettering) within a Î²-sheet structure. The polarity of the surface residues is shown with hydrophobic residues depicted in orange, hydrophilic in blue and white indicating neutral polarity. (C) Rotating the model 180Â° horizontally shows that M177 is located close to F182, which is involved in a cation-Ï interaction with the amino group of glycine. (D) Top view of M177, relative to the ligand-binding domain, rotated 90Â° vertically from B. Thus, mutation M177R is predicted to result in the loss of a hydrophobic side-chain and replacement with a positively-charged side chain. This substitution is predicted to disturb the local fold of the extracellular domain and have a knock-on effect for positioning of the critical ligand-binding residue F182.</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
    <fig id="f0030">
      <label>Fig.Â 6</label>
      <caption>
        <p>Cell-surface biotinylation assays for GlyR Î² subunit mutations. (A) Cell-surface biotinylation assays on heteromeric Î±<sub>1</sub>Î² GlyRs expressed in HEK293 cells revealed that all three GlyR Î² subunit mutants (M177R, L285R and W310C) were expressed at similar levels in whole-cell protein expression (total) compared to an actin control. However, mutations L285R and W310C revealed markedly reduced cell-surface protein expression (surface) compared to wild-type or the M177R mutant. 70Â Î¼g of protein lysates were loaded in the each lane. (B) Quantification of cell surface and whole cell expression of the GlyR Î² subunit mutants using ImageJ software, with values expressed as a percentage of wild-type GlyR Î² subunit expression. p-Values were calculated relative to wild-type GlyR Î² expression using an unpaired <italic>t</italic>-test; ***Â =Â pÂ &lt;Â 0.001.</p>
      </caption>
      <graphic xlink:href="gr6"/>
    </fig>
    <fig id="f0035">
      <label>Fig.Â 7</label>
      <caption>
        <p>Functional characterization of human GlyR Î²<sup>L285R</sup> and Î²<sup>W310C</sup> mutations using the EYFP assay. (A, B) Mean glycine doseâresponse curves for Î±<sub>1</sub>, Î±<sub>1</sub>Î², Î±<sub>1</sub>Î²<sup>L285R</sup>, Î±<sub>1</sub>Î²Î²<sup>L285R</sup>, Î±<sub>1</sub>Î²<sup>W310C</sup> and Î±<sub>1</sub>Î²Î²<sup>W310C</sup> GlyRs. The percentage quench is plotted against the applied glycine concentration (Î¼M). Averaged parameters of best fit to doseâresponse curves are summarized in <xref rid="t0010" ref-type="table">TableÂ 2</xref>. (C) Maximal changes in fluorescence. ÎF<sub>max</sub> is the initial fluorescence value minus the final fluorescence value and is represented in fluorescence units. p-Values were calculated relative to Î±<sub>1</sub>Î² GlyR heteromers by unpaired <italic>t</italic>-test: * pÂ &lt;Â 0.05, ** pÂ &lt;Â 0.01, *** pÂ &lt;Â 0.001. (D) Maximal changes in fluorescence for GlyR subunits transfected in different Î±:Î² ratios while the amount of Î±<sub>1</sub> transfected was held constant. * pÂ &lt;Â 0.05 by unpaired <italic>t</italic>-test. (E) Inhibition by 100Â Î¼M lindane. The inhibition of currents activated by 10Â Î¼M glycine by 100Â Î¼M lindane is represented as a percentage reduction of the control maximal fluorescent quench. p-Values were calculated relative to GlyR Î±<sub>1</sub> homomers by unpaired <italic>t</italic>-test: * pÂ &lt;Â 0.05, ** pÂ &lt;Â 0.01, *** pÂ &lt;Â 0.001. (F) Fluorescent quench in the presence of sodium iodide (no glycine). p-Values were calculated relative to GlyR Î±<sub>1</sub>Î² heteromers by unpaired <italic>t</italic>-test: * pÂ &lt;Â 0.05, ** pÂ &lt;Â 0.01, *** pÂ &lt;Â 0.001. All data points displayed in this figure represent the average quench from four experiments comprising three wells each withÂ &gt;Â 200 cells per well.</p>
      </caption>
      <graphic xlink:href="gr7"/>
    </fig>
    <fig id="f0040">
      <label>Fig.Â 8</label>
      <caption>
        <p>Functional characterization of human GlyRs containing Î²<sup>L285R</sup> and Î²<sup>W310C</sup> using electrophysiology. (A) Sample glycine doseâresponse traces of Î±<sub>1</sub>Î², Î±<sub>1</sub>Î²<sup>L285R</sup> and Î±<sub>1</sub>Î²<sup>W310C</sup> GlyRs. Filled bars indicate the applied glycine concentrations in Î¼M and non-filled bars the application of 100Â Î¼M lindane. The effect of 100Â Î¼M lindane on homomeric Î±<sub>1</sub> subunit GlyRs is included as a control. (B) Normalized glycine doseâresponse curves for the GlyRs shown in panel A. (C) Inhibition of leak currents in Î±<sub>1</sub>Î²<sup>L285R</sup> GlyRs by 100Â Î¼M picrotoxin (PTX). The inward current transient was always observed (nÂ =Â 5 cells). (D) Spontaneous single-channel currents for Î±<sub>1</sub>Î²<sup>L285R</sup> GlyRs. Most openings were of 2â10Â ms duration as illustrated in Patch 1. Occasionally, with multiple channels in the patch, longer activations were also observed, as in Patch 2. (E) Mean currents activated by 100Â Î¼M glycine in cells expressing Î±<sub>1</sub>Î² GlyRs in a 1:1 ratio relative to those in cells expressing Î±<sub>1</sub>Î²<sup>W310C</sup> GlyRs in a 1:10 ratio. p-Values were calculated relative to GlyR Î±<sub>1</sub>Î² heteromers by unpaired <italic>t</italic>-test: ** pÂ &lt;Â 0.01.</p>
      </caption>
      <graphic xlink:href="gr8"/>
    </fig>
    <fig id="f0045">
      <label>Fig.Â 9</label>
      <caption>
        <p>Functional characterization of human GlyRs containing Î²<sup>M177R</sup> using the EYFP assay and electrophysiology. (A) Mean glycine doseâresponse curves for Î±<sub>1</sub>, Î±<sub>1</sub>Î², Î±<sub>1</sub>Î²<sup>M177R</sup> and Î±<sub>1</sub>Î²Î²<sup>M177R</sup> GlyRs using the EYFP assay. The percentage quench is plotted against the applied glycine concentration (Î¼M). Averaged parameters of best fit to doseâresponse curves are summarized in <xref rid="t0015" ref-type="table">TableÂ 3</xref>. All data points represent the average quench from four experiments comprising three wells each withÂ &gt;Â 200 cells per well. (B) Maximal changes in fluorescence. ÎF<sub>max</sub> is the initial fluorescence value minus the final fluorescence value and is represented in fluorescence units. p-Values were calculated relative to Î±<sub>1</sub>Î² GlyR heteromers by unpaired <italic>t</italic>-test: * pÂ &lt;Â 0.05, *** pÂ &lt;Â 0.001. (C) Inhibition by 100Â Î¼M lindane. The inhibition of currents activated by 100Â Î¼M glycine by 100Â Î¼M lindane is represented as a percentage reduction of the control maximal fluorescent quench. p-Values were calculated relative to GlyR Î±<sub>1</sub> homomers by unpaired <italic>t</italic>-test: ** pÂ &lt;Â 0.01, *** pÂ &lt;Â 0.001. (D) Normalized glycine doseâresponse results using whole-cell patch-clamp electrophysiology for the GlyRs shown in panel E. The normalized maximal currents of cells transfected with the indicated plasmid vectors are plotted against the applied glycine concentration (Î¼M). (E) Sample glycine doseâresponse traces. Filled bars indicate the applied glycine concentration in Î¼M and non-filled bars the application of 100Â Î¼M lindane.</p>
      </caption>
      <graphic xlink:href="gr9"/>
    </fig>
    <table-wrap id="t0005" position="float">
      <label>TableÂ 1</label>
      <caption>
        <p>Single nucleotide variants in <italic>GLRB</italic> associated with startle disease/hyperekplexia. Mutations G229D/IVS5+5G&gt;A, M177R, and S321F were reported previously (<xref rid="bb0010 bb0165 bb0230" ref-type="bibr">Al-Owain et al., 2012; Lee et al., 2012; Rees et al., 2002</xref>). Panel: DNA sequence electropherograms for the two novel mutations (c.920_921ÎInsGA/L285R and c.G996T/p.W310C) reported in this study. Bioinformatics analysis was conducted using SIFT (<xref rid="bb0155" ref-type="bibr">Kumar et al., 2009</xref>) with ENSP00000264428 and Polyphen-2 (<xref rid="bb0005" ref-type="bibr">Adzhubei et al., 2010</xref>).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">Position</th>
            <th align="left">Exon</th>
            <th align="left">Protein precursor/mature</th>
            <th align="left">Type</th>
            <th align="left">SIFT</th>
            <th align="left">Polyphen-2</th>
            <th align="left">Overall prediction</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">c.T596G</td>
            <td align="left">6</td>
            <td align="left">M199R/M177R</td>
            <td align="left">Missense</td>
            <td align="left">Damaging (0)</td>
            <td align="left">Possibly damaging (0.802)</td>
            <td align="left">Pathogenic</td>
          </tr>
          <tr>
            <td align="left">c.G752A</td>
            <td align="left">8</td>
            <td align="left">G251D/G229D</td>
            <td align="left">Missense</td>
            <td align="left">Damaging (0)</td>
            <td align="left">Probably damaging (1.0)</td>
            <td align="left">Pathogenic</td>
          </tr>
          <tr>
            <td align="left">IVS5+5G&gt;A</td>
            <td align="left">â</td>
            <td align="left">â</td>
            <td align="left">Splice site</td>
            <td align="left">â</td>
            <td align="left">â</td>
            <td align="left">Pathogenic</td>
          </tr>
          <tr>
            <td align="left">c.920_921ÎInsGA</td>
            <td align="left">9</td>
            <td align="left">L307R/L285R</td>
            <td align="left">Missense</td>
            <td align="left">Damaging (0)</td>
            <td align="left">Probably damaging (0.997)</td>
            <td align="left">Pathogenic</td>
          </tr>
          <tr>
            <td align="left">c.G996T</td>
            <td align="left">9</td>
            <td align="left">W332C/W310C</td>
            <td align="left">Missense</td>
            <td align="left">Damaging (0)</td>
            <td align="left">Probably damaging (0.999)</td>
            <td align="left">Pathogenic</td>
          </tr>
          <tr>
            <td align="left">c.C1028T</td>
            <td align="left">9</td>
            <td align="left">S343F/S321F</td>
            <td align="left">Missense</td>
            <td align="left">Damaging (0)</td>
            <td align="left">Probably damaging (0.990)</td>
            <td align="left">Pathogenic</td>
          </tr>
          <tr>
            <td colspan="7" align="left">
              <inline-graphic xlink:href="fx1.gif"/>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="t0010" position="float">
      <label>TableÂ 2</label>
      <caption>
        <p>Properties of human GlyRs containing Î²<sup>L285R</sup> and Î²<sup>W310C</sup> subunits using the EYFP assay. EC<sub>50</sub> values, Hill coefficients (n<sub>H</sub>), the maximal fluorescence changes (ÎF<sub>max</sub>), the maximal percentages of quenched cells (cells<sub>quench</sub>) and the inhibition of 10Â Î¼M glycine currents by 100Â Î¼M lindane (LIN<sub>inh</sub>) are represented. p-Values were calculated relative to GlyR Î±<sub>1</sub>Î² subunit heteromers except for inhibition by lindane, which was compared to GlyR Î±<sub>1</sub> subunit homomers by unpaired <italic>t</italic>-test.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th colspan="6" align="left">EYFP assay<hr/></th>
          </tr>
          <tr>
            <th align="left">EC<sub>50</sub> (Î¼M)</th>
            <th align="left">n<sub>H</sub></th>
            <th align="left">ÎF<sub>max</sub> (FU)</th>
            <th align="left">cells<sub>quench</sub> (%)</th>
            <th align="left">LIN<sub>inh</sub> (%)</th>
            <th align="left">n</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">Î±<sub>1</sub></td>
            <td align="char">8Â Â±Â 1</td>
            <td align="char">1.7Â Â±Â 0.1</td>
            <td align="char">44Â Â±Â 1</td>
            <td align="char">94Â Â±Â 2</td>
            <td align="char">111Â Â±Â 4</td>
            <td align="left">12</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²</td>
            <td align="char">5Â Â±Â 1</td>
            <td align="char">3.9Â Â±Â 2.2</td>
            <td align="char">44Â Â±Â 2</td>
            <td align="char">96Â Â±Â 2</td>
            <td align="char">38Â Â±Â 2<xref rid="tf0015" ref-type="table-fn">âââ</xref></td>
            <td align="left">12</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²<sup>L285R</sup></td>
            <td align="char">4Â Â±Â 1</td>
            <td align="char">0.9Â Â±Â 0.1<xref rid="tf0005" ref-type="table-fn">â</xref></td>
            <td align="char">19Â Â±Â 2<xref rid="tf0015" ref-type="table-fn">âââ</xref></td>
            <td align="char">86Â Â±Â 7</td>
            <td align="char">6Â Â±Â 7<xref rid="tf0015" ref-type="table-fn">âââ</xref></td>
            <td align="left">12</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²Î²<sup>L285R</sup></td>
            <td align="char">4Â Â±Â 1</td>
            <td align="char">0.9Â Â±Â 0.1<xref rid="tf0005" ref-type="table-fn">â</xref></td>
            <td align="char">19Â Â±Â 2<xref rid="tf0015" ref-type="table-fn">âââ</xref></td>
            <td align="char">83Â Â±Â 5</td>
            <td align="char">14Â Â±Â 7<xref rid="tf0015" ref-type="table-fn">âââ</xref></td>
            <td align="left">12</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²<sup>W310C</sup></td>
            <td align="char">13Â Â±Â 2<xref rid="tf0005" ref-type="table-fn">â</xref></td>
            <td align="char">4.3Â Â±Â 1.8</td>
            <td align="char">32Â Â±Â 3<xref rid="tf0005" ref-type="table-fn">â</xref></td>
            <td align="char">81Â Â±Â 5<xref rid="tf0005" ref-type="table-fn">â</xref></td>
            <td align="char">51Â Â±Â 10<xref rid="tf0010" ref-type="table-fn">ââ</xref></td>
            <td align="left">12</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²Î²<sup>W310C</sup></td>
            <td align="char">11Â Â±Â 1<xref rid="tf0010" ref-type="table-fn">ââ</xref></td>
            <td align="char">5.1Â Â±Â 1.5</td>
            <td align="char">32Â Â±Â 1<xref rid="tf0010" ref-type="table-fn">ââ</xref></td>
            <td align="char">90Â Â±Â 1<xref rid="tf0005" ref-type="table-fn">â</xref></td>
            <td align="char">32Â Â±Â 12<xref rid="tf0015" ref-type="table-fn">âââ</xref></td>
            <td align="left">12</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tf0005">
          <label>â</label>
          <p>pÂ &lt;Â 0.05.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tf0010">
          <label>ââ</label>
          <p>pÂ &lt;Â 0.01.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tf0015">
          <label>âââ</label>
          <p>pÂ &lt;Â 0.001.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t0015" position="float">
      <label>TableÂ 3</label>
      <caption>
        <p>Properties of Î±<sub>1</sub>Î², Î±<sub>1</sub>Î²<sup>L285R</sup>, Î±<sub>1</sub>Î²<sup>W310C</sup> and Î²<sup>M177R</sup> GlyRs using whole-cell patch-clamp electrophysiology. EC<sub>50</sub> values, Hill coefficients (n<sub>H</sub>) and the maximal currents (I<sub>max</sub>) are represented. p-Values were calculated relative to the wild-type Î±<sub>1</sub>Î² subunit GlyRs by unpaired <italic>t</italic>-test.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th colspan="4" align="left">Whole-cell patch-clamp electrophysiology<hr/></th>
          </tr>
          <tr>
            <th align="left">EC<sub>50</sub> (Î¼M)</th>
            <th align="left">n<sub>H</sub></th>
            <th align="left">I<sub>max</sub> (nA)</th>
            <th align="left">n</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²</td>
            <td align="left">39Â Â±Â 4</td>
            <td align="left">2.4Â Â±Â 0.2</td>
            <td align="left">14Â Â±Â 3</td>
            <td align="left">5</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²<sup>L285R</sup></td>
            <td align="left">49Â Â±Â 7</td>
            <td align="left">1.2Â Â±Â 0.1<xref rid="tf0020" ref-type="table-fn">ââ</xref></td>
            <td align="left">9Â Â±Â 4</td>
            <td align="left">3</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²<sup>W310C</sup></td>
            <td align="left">28, 58</td>
            <td align="left">1.7, 4.0</td>
            <td align="left">0.22, 0.15</td>
            <td align="left">2</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²<sup>M177R</sup></td>
            <td align="left">162Â Â±Â 3<xref rid="tf0025" ref-type="table-fn">âââ</xref></td>
            <td align="left">2.2Â Â±Â 0.1</td>
            <td align="left">8Â Â±Â 1</td>
            <td align="left">5</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tf0020">
          <label>ââ</label>
          <p>pÂ &lt;Â 0.01.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tf0025">
          <label>âââ</label>
          <p>pÂ &lt;Â 0.001.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t0020" position="float">
      <label>TableÂ 4</label>
      <caption>
        <p>Properties of Î±<sub>1</sub>Î²<sup>M177R</sup> GlyRs using the EYFP assay. EC<sub>50</sub> values, Hill coefficients (n<sub>H</sub>), the maximal fluorescence changes (ÎF<sub>max</sub>), the maximal percentages of quenched cells (cells<sub>quench</sub>) and the inhibition of 100Â Î¼M glycine currents by blocking with 100Â Î¼M lindane (LIN<sub>inh</sub>) are represented. p-Values were calculated relative to GlyR Î±<sub>1</sub>Î² subunit heteromers except for inhibition by lindane, which was compared to GlyR Î±<sub>1</sub> subunit homomers by unpaired <italic>t</italic>-test.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th colspan="6" align="left">EYFP assay<hr/></th>
          </tr>
          <tr>
            <th align="left">EC<sub>50</sub> (Î¼M)</th>
            <th align="left">n<sub>H</sub></th>
            <th align="left">ÎF<sub>max</sub> (FU)</th>
            <th align="left">cells<sub>quench</sub> (%)</th>
            <th align="left">LIN<sub>inh</sub> (%)</th>
            <th align="left">n</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">Î±<sub>1</sub></td>
            <td align="char">25Â Â±Â 5</td>
            <td align="char">1.5Â Â±Â 0.1</td>
            <td align="char">46Â Â±Â 2</td>
            <td align="char">97Â Â±Â 1</td>
            <td align="char">92Â Â±Â 5</td>
            <td align="left">12</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²</td>
            <td align="char">17Â Â±Â 5</td>
            <td align="char">1.7Â Â±Â 0.1</td>
            <td align="char">50Â Â±Â 1</td>
            <td align="char">96Â Â±Â 1</td>
            <td align="char">42Â Â±Â 6<xref rid="tf0040" ref-type="table-fn">âââ</xref></td>
            <td align="left">12</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²<sup>M177R</sup></td>
            <td align="char">64Â Â±Â 13<xref rid="tf0030" ref-type="table-fn">â</xref></td>
            <td align="char">3.4Â Â±Â 1.9</td>
            <td align="char">29Â Â±Â 1<xref rid="tf0040" ref-type="table-fn">âââ</xref></td>
            <td align="char">81Â Â±Â 2<xref rid="tf0040" ref-type="table-fn">âââ</xref></td>
            <td align="char">54Â Â±Â 8<xref rid="tf0030" ref-type="table-fn">â</xref></td>
            <td align="left">12</td>
          </tr>
          <tr>
            <td align="left">Î±<sub>1</sub>Î²Î²<sup>M177R</sup></td>
            <td align="char">45Â Â±Â 14</td>
            <td align="char">3.4Â Â±Â 1.9</td>
            <td align="char">31Â Â±Â 2<xref rid="tf0030" ref-type="table-fn">â</xref></td>
            <td align="char">84Â Â±Â 2<xref rid="tf0040" ref-type="table-fn">âââ</xref></td>
            <td align="char">60Â Â±Â 7<xref rid="tf0035" ref-type="table-fn">ââ</xref></td>
            <td align="left">12</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tf0030">
          <label>â</label>
          <p>pÂ &lt;Â 0.05.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tf0035">
          <label>ââ</label>
          <p>pÂ &lt;Â 0.01.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tf0040">
          <label>âââ</label>
          <p>pÂ &lt;Â 0.001.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>